CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | caffeic acid |
|
Accession: | CHEBI:36281
|
browse the term
|
Definition: | A hydroxycinnamic acid that is cinnamic acid in which the phenyl ring is substituted by hydroxy groups at positions 3 and 4. It exists in cis and trans forms; the latter is the more common. |
Synonyms: | exact_synonym: | 3-(3,4-dihydroxyphenyl)prop-2-enoic acid |
| related_synonym: | Formula=C9H8O4; InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13); InChIKey=QAIPRVGONGVQAS-UHFFFAOYSA-N; SMILES=OC(=O)C=Cc1ccc(O)c(O)c1 |
| xref: | Beilstein:2210883; HMDB:HMDB0001964; KEGG:C01481; LINCS:LSM-5272; PMID:11373473; PMID:15778121; PMID:18061431; PMID:18314336; PMID:18482095; PMID:20542693; PMID:8340025; Reaxys:2210883 |
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases localization |
ISO |
acteoside promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased localization of AHR protein] acteoside results in decreased localization of AHR protein |
CTD |
PMID:21756928 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases localization |
ISO |
acteoside results in increased localization of ARNT protein |
CTD |
PMID:21756928 |
|
NCBI chr 2:196,594,178...196,651,486
Ensembl chr 2:196,594,303...196,651,179
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions decreases secretion |
ISO |
acteoside results in decreased expression of CCL2 mRNA acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA] acteoside results in decreased secretion of CCL2 protein |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND1 protein |
CTD |
PMID:17634406 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND2 protein |
CTD |
PMID:17634406 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND3 protein |
CTD |
PMID:17634406 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
acteoside results in decreased expression of CCNE1 protein |
CTD |
PMID:17634406 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
acteoside results in decreased expression of and results in decreased activity of CDK2 protein |
CTD |
PMID:17634406 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases activity multiple interactions |
ISO |
acteoside results in decreased activity of CDK4 protein acteoside promotes the reaction [CDKN1A protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK4 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
ISO |
acteoside promotes the reaction [CDKN1A protein binds to CDK6 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK6 protein]; acteoside results in decreased expression of and results in decreased activity of CDK6 protein |
CTD |
PMID:17634406 |
|
NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
acteoside results in increased expression of CDKN1A mRNA; acteoside results in increased expression of CDKN1A protein acteoside promotes the reaction [CDKN1A protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1A protein binds to CDK6 protein] |
CTD |
PMID:17634406 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
acteoside results in increased expression of CDKN1B mRNA; acteoside results in increased expression of CDKN1B protein acteoside promotes the reaction [CDKN1B protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK6 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases secretion decreases expression multiple interactions |
ISO |
acteoside results in decreased secretion of CXCL10 protein acteoside results in decreased expression of CXCL10 mRNA acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]; acteoside promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
acteoside results in increased expression of CYP1A1 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
acteoside inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:14672760 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[acteoside results in decreased phosphorylation of RB1 protein] promotes the reaction [RB1 protein binds to E2F1 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases phosphorylation multiple interactions |
ISO |
acteoside results in decreased phosphorylation of EGFR protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
acteoside results in decreased expression of ICAM1 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ifng |
interferon gamma |
decreases expression multiple interactions |
ISO |
acteoside results in decreased expression of IFNG mRNA acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21371465 PMID:21756928 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO |
acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] acteoside results in decreased expression of IL6 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
acteoside inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; acteoside inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ITGB2 protein] |
CTD |
PMID:16393473 |
|
NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions decreases phosphorylation |
ISO |
acteoside results in increased phosphorylation of MAPK1 protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein] acteoside results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO |
acteoside results in decreased phosphorylation of MAPK3 protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein] acteoside results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Nox1 |
NADPH oxidase 1 |
decreases activity |
ISO |
acteoside results in decreased activity of NOX1 protein |
CTD |
PMID:16393473 |
|
NCBI chr X:104,909,328...104,932,508
Ensembl chr X:104,909,326...104,932,508
|
|
G |
Ptgds |
prostaglandin D2 synthase |
affects binding |
ISO |
acteoside binds to PTGDS protein |
CTD |
PMID:26456343 |
|
NCBI chr 3:2,686,125...2,689,059
Ensembl chr 3:2,686,123...2,689,084
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[acteoside co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PTGS2 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation multiple interactions |
ISO |
acteoside results in decreased phosphorylation of RB1 protein [acteoside results in decreased phosphorylation of RB1 protein] promotes the reaction [RB1 protein binds to E2F1 protein] |
CTD |
PMID:17634406 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation multiple interactions decreases phosphorylation |
ISO |
acteoside results in increased phosphorylation of RELA protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] acteoside results in decreased phosphorylation of RELA protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Smad2 |
SMAD family member 2 |
increases phosphorylation |
ISO |
acteoside results in increased phosphorylation of SMAD2 protein |
CTD |
PMID:17634406 |
|
NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
|
|
G |
Smad3 |
SMAD family member 3 |
increases phosphorylation |
ISO |
acteoside results in increased phosphorylation of SMAD3 protein |
CTD |
PMID:17634406 |
|
NCBI chr 8:68,569,530...68,678,349
Ensembl chr 8:68,569,530...68,678,349
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression |
ISO |
acteoside results in decreased expression of SOD2 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
[acteoside co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
acteoside results in increased expression of TGFB1 mRNA |
CTD |
PMID:17634406 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21756928 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression |
ISO |
acteoside results in decreased expression of VCAM1 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of ABCC1 protein] |
CTD |
PMID:25043994 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of ABCC2 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of ACHE protein |
CTD |
PMID:20854806 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Acly |
ATP citrate lyase |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of ACLY mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:23146752 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Alb |
albumin |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of ALB protein] Chlorogenic Acid affects the reaction [2,2'-azobis(2-amidinopropane) results in increased degradation of ALB protein] |
CTD |
PMID:11322927 PMID:23146752 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aqp1 |
aquaporin 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of AQP1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of AQP3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Ar |
androgen receptor |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of AR mRNA |
CTD |
PMID:20706672 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of BAMBI mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of BAMBI protein] |
CTD |
PMID:23146752 |
|
NCBI chr17:56,905,419...56,909,675
Ensembl chr17:56,905,112...56,909,992
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
Chlorogenic Acid inhibits the reaction [Aluminum Chloride results in increased expression of BAX protein]; Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of BAX mRNA] Chlorogenic Acid inhibits the reaction [Methotrexate results in increased expression of BAX protein] |
CTD |
PMID:25043994 PMID:28479099 PMID:28623112 PMID:33242462 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein] Chlorogenic Acid inhibits the reaction [Aluminum Chloride results in decreased expression of BCL2 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of BCL2 mRNA] |
CTD |
PMID:28479099 PMID:28623112 PMID:33242462 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of CASP3 mRNA]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein] Chlorogenic Acid inhibits the reaction [Methotrexate results in increased activity of CASP3 protein] |
CTD |
PMID:25043994 PMID:28479099 PMID:33242462 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [aluminum chloride results in increased expression of CASP8 protein] |
CTD |
PMID:28623112 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [Methotrexate results in increased activity of CASP9 protein] |
CTD |
PMID:28479099 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased activity of CAT protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in decreased activity of CAT protein] Chlorogenic Acid inhibits the reaction [Aluminum Chloride results in decreased activity of CAT protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of CAT mRNA] |
CTD |
PMID:28479099 PMID:28623112 PMID:31390532 PMID:33242462 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of CCL2 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of CCL2 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein] |
CTD |
PMID:26079055 PMID:31306686 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of CCND1 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of CD44 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of CDH1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
ISO EXP |
Chlorogenic Acid results in increased expression of COL1A1 mRNA Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA] |
CTD |
PMID:20706672 PMID:23146752 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of phenylpyruvic acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Citric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Succinic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein] |
CTD |
PMID:24709313 |
|
NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
|
|
G |
Cs |
citrate synthase |
increases activity |
ISO |
Chlorogenic Acid results in increased activity of CS protein |
CTD |
PMID:31306686 |
|
NCBI chr 7:2,752,680...2,778,963
Ensembl chr 7:2,752,680...2,778,963
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of CXCL1 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of CXCL1 protein] |
CTD |
PMID:26079055 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cygb |
cytoglobin |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of CYGB mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:105,618,325...105,628,091
Ensembl chr10:105,618,326...105,628,091
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of CYP19A1 protein |
CTD |
PMID:29899696 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of CYP2E1 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Dsg3 |
desmoglein 3 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of DSG3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr18:15,652,948...15,688,605
Ensembl chr18:15,650,526...15,688,284
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of EGF mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression |
EXP |
Chlorogenic Acid results in decreased expression of ESR1 protein |
CTD |
PMID:29899696 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of ESR2 protein |
CTD |
PMID:29899696 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
F10 |
coagulation factor X |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of F10 protein |
CTD |
PMID:27704645 |
|
NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
|
|
G |
F2 |
coagulation factor II |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of F2 protein |
CTD |
PMID:27704645 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of FASN mRNA |
CTD |
PMID:21870829 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fbn1 |
fibrillin 1 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of FBN1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:117,569,708...117,766,160
Ensembl chr 3:117,569,697...117,766,120
|
|
G |
Fbn2 |
fibrillin 2 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of FBN2 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr18:53,068,495...53,272,254
Ensembl chr18:53,068,495...53,181,503
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of FGF1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of FSHB protein] |
CTD |
PMID:33242462 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Fshr |
follicle stimulating hormone receptor |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of FSHR protein |
CTD |
PMID:29899696 |
|
NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
Chlorogenic Acid results in increased expression of GCLC mRNA Chlorogenic Acid promotes the reaction [Acetaminophen results in increased expression of GCLC mRNA] |
CTD |
PMID:29136249 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of GCLM mRNA |
CTD |
PMID:29136249 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased activity of GPT protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in increased activity of GPT protein] Chlorogenic Acid inhibits the reaction [aluminum chloride results in increased activity of GPT protein] |
CTD |
PMID:28479099 PMID:28623112 PMID:31390532 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of GPX1 mRNA] |
CTD |
PMID:33242462 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Grn |
granulin precursor |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of GRN mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:90,377,103...90,383,207
Ensembl chr10:90,376,933...90,383,205
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Methotrexate results in decreased activity of GSR protein] Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased activity of GSR protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of GSR mRNA] |
CTD |
PMID:28479099 PMID:33242462 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases activity |
ISO |
Chlorogenic Acid results in increased activity of GSTA1 protein |
CTD |
PMID:15944151 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Gsta6 |
glutathione S-transferase alpha 6 |
increases activity |
ISO |
Chlorogenic Acid results in increased activity of GSTA1 protein |
CTD |
PMID:15944151 |
|
NCBI chr 9:27,475,273...27,533,939
Ensembl chr 9:27,475,273...27,511,176
|
|
G |
Has1 |
hyaluronan synthase 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of HAS1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 1:59,720,612...59,732,409
Ensembl chr 1:59,720,612...59,732,409
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:34,357,372...34,537,798
Ensembl chr11:34,352,287...34,526,931
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions decreases expression |
EXP ISO |
[tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein] Chlorogenic Acid results in decreased expression of HMGCR mRNA |
CTD |
PMID:20696151 PMID:21870829 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of HMOX1 protein] Chlorogenic Acid results in increased expression of HMOX1 mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of HMOX1 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of HMOX1 protein] |
CTD |
PMID:25043994 PMID:29136249 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of HSPB1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of IL1A mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B mRNA] Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of IL1B mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of IL1B protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of IL1B protein] |
CTD |
PMID:23146752 PMID:24709313 PMID:26079055 PMID:33242462 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
Chlorogenic Acid results in increased expression of IL6 mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of IL6 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of IL6 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of IL6 protein] Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of IL6 protein]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 mRNA] |
CTD |
PMID:21870829 PMID:23146752 PMID:26079055 PMID:31390532 PMID:33242462 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itgb2 |
integrin subunit beta 2 |
decreases expression multiple interactions |
EXP |
Chlorogenic Acid results in decreased expression of ITGB2 protein Chlorogenic Acid inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of ITGB2 protein] |
CTD |
PMID:21414398 |
|
NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of JUN protein] |
CTD |
PMID:15944151 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Krt5 |
keratin 5 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of KRT5 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 7:143,320,142...143,324,536
Ensembl chr 7:143,316,920...143,453,546
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
[tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein] |
CTD |
PMID:20696151 |
|
NCBI chr19:37,913,333...37,916,799
Ensembl chr19:37,913,336...37,916,813
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of LHB protein] |
CTD |
PMID:33242462 |
|
NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
EXP |
[tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein] |
CTD |
PMID:20696151 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of MAOA protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
Chlorogenic Acid results in decreased activity of MAOB protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,430,694...6,533,520
Ensembl chr X:6,430,594...6,533,534
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAP2K4 protein] |
CTD |
PMID:15944151 |
|
NCBI chr10:52,196,121...52,301,887
Ensembl chr10:52,196,124...52,290,657
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] Chlorogenic Acid promotes the reaction [Acetaminophen results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15944151 PMID:29136249 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:15944151 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] Chlorogenic Acid promotes the reaction [Acetaminophen results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15944151 PMID:29136249 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mc1r |
melanocortin 1 receptor |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of MC1R mRNA |
CTD |
PMID:20706672 |
|
NCBI chr19:56,215,420...56,219,987
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Chlorogenic Acid results in decreased activity of MGST1 protein |
CTD |
PMID:16125204 |
|
NCBI chr 4:172,119,382...172,134,609
Ensembl chr 4:172,119,331...172,134,607
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of MPO protein] |
CTD |
PMID:26079055 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of COX1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
[Chlorogenic Acid co-treated with Zymosan] results in decreased expression of COX2 protein; Chlorogenic Acid inhibits the reaction [Zymosan results in increased expression of COX2 protein] |
CTD |
PMID:30481570 |
|
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MT1 mRNA]; Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MT1 protein] |
CTD |
PMID:31390532 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of MYD88 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of MYD88 protein] Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of MYD88 protein] |
CTD |
PMID:23146752 PMID:26079055 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases localization multiple interactions increases response to substance affects localization decreases response to substance |
ISO |
Chlorogenic Acid results in increased localization of NFE2L2 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Chlorogenic Acid co-treated with Acetaminophen] results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein]; [Chlorogenic Acid co-treated with Acetaminophen] results in increased activity of and affects the localization of NFE2L2 protein; [Chlorogenic Acid co-treated with Acetaminophen] results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein; U 0126 inhibits the reaction [[Chlorogenic Acid co-treated with Acetaminophen] results in increased phosphorylation of and affects the localization of and results in increased activity of NFE2L2 protein] [Chlorogenic Acid co-treated with Acetaminophen] affects the localization of and results in increased activity of NFE2L2 protein; Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of NFE2L2 mRNA] NFE2L2 results in increased susceptibility to Chlorogenic Acid Chlorogenic Acid affects the localization of NFE2L2 protein NFE2L2 gene mutant form results in decreased susceptibility to Chlorogenic Acid |
CTD |
PMID:15944151 PMID:29136249 PMID:33242462 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein] Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:20026373 PMID:23146752 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of NFKBIB protein] |
CTD |
PMID:20026373 |
|
NCBI chr 1:86,941,073...86,948,845
Ensembl chr 1:86,941,074...86,948,845
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Chlorogenic Acid inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of NOS2 mRNA]; Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein] Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in increased expression of NOS2 protein] |
CTD |
PMID:20026373 PMID:23146752 PMID:28479099 PMID:31306686 PMID:33242462 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of NOS3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity increases expression multiple interactions |
ISO |
Chlorogenic Acid results in increased activity of NQO1 protein Chlorogenic Acid results in increased expression of NQO1 mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of NQO1 mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of NQO1 protein] |
CTD |
PMID:15944151 PMID:29136249 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Ocln |
occludin |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of OCLN mRNA]; Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of OCLN protein] |
CTD |
PMID:31390532 |
|
NCBI chr 2:30,527,327...30,577,218
Ensembl chr 2:30,527,715...30,577,218
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Chlorogenic Acid promotes the reaction [Cisplatin results in increased expression of PCNA protein] |
CTD |
PMID:25043994 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of PECAM1 protein] |
CTD |
PMID:21414398 |
|
NCBI chr10:94,850,971...94,913,202
|
|
G |
Pgr |
progesterone receptor |
increases expression decreases expression |
ISO |
Chlorogenic Acid results in increased expression of PGR mRNA Chlorogenic Acid results in decreased expression of PGR mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of PIK3R1 mRNA |
CTD |
PMID:21870829 |
|
NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of PLOD3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr12:22,716,421...22,726,982
Ensembl chr12:22,716,423...22,726,982
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression decreases expression |
ISO |
Chlorogenic Acid results in increased expression of PPARG mRNA Chlorogenic Acid results in decreased expression of PPARG mRNA |
CTD |
PMID:20706672 PMID:21870829 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
multiple interactions |
ISO |
[Chlorogenic Acid co-treated with Acetaminophen] results in decreased expression of PPP2R1A protein |
CTD |
PMID:29136249 |
|
NCBI chr 1:60,717,386...60,736,629
Ensembl chr 1:60,717,386...60,736,609
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
multiple interactions |
ISO |
[Chlorogenic Acid co-treated with Acetaminophen] results in decreased expression of PPP5C protein |
CTD |
PMID:29136249 |
|
NCBI chr 1:78,944,054...78,968,361
Ensembl chr 1:78,944,040...78,968,329
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; Chlorogenic Acid inhibits the reaction [Methotrexate results in increased expression of PTGS2 protein] Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of PTGS2 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of and results in increased expression of PTGS2 protein] |
CTD |
PMID:20026373 PMID:23146752 PMID:25043994 PMID:28479099 PMID:31306686 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rad23a |
RAD23 homolog A, nucleotide excision repair protein |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of RAD23A mRNA |
CTD |
PMID:20706672 |
|
NCBI chr19:25,949,488...25,956,677
Ensembl chr19:25,949,490...25,955,391
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of RARA mRNA |
CTD |
PMID:20706672 |
|
NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of and results in increased phosphorylation of and affects the localization of RELA protein]; Chlorogenic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of RELA protein] |
CTD |
PMID:20026373 PMID:26079055 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rxra |
retinoid X receptor alpha |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of RXRA mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Sell |
selectin L |
multiple interactions |
EXP |
[Chlorogenic Acid co-treated with lipopolysaccharide, E. coli O26-B6] results in increased expression of SELL protein; Chlorogenic Acid inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in decreased expression of SELL protein] |
CTD |
PMID:21414398 |
|
NCBI chr13:82,369,820...82,387,774
Ensembl chr13:82,369,493...82,387,631
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC11A2 mRNA]; Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC11A2 protein] |
CTD |
PMID:31390532 |
|
NCBI chr 7:142,025,812...142,062,892
Ensembl chr 7:142,025,815...142,063,212
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in decreased expression of SLC22A2 protein] |
CTD |
PMID:25043994 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of SLC2A4 mRNA |
CTD |
PMID:21870829 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression multiple interactions |
ISO |
Chlorogenic Acid results in increased expression of SOD2 mRNA Chlorogenic Acid inhibits the reaction [sodium arsenite results in decreased expression of SOD2 mRNA] |
CTD |
PMID:33242462 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sod3 |
superoxide dismutase 3 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of SOD3 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr14:60,958,583...60,971,143
Ensembl chr14:60,958,592...60,964,324
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in decreased expression of SQSTM1 protein] |
CTD |
PMID:29136249 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Srd5a2 |
steroid 5 alpha-reductase 2 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of SRD5A2 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 6:25,279,635...25,315,501
Ensembl chr 6:25,279,626...25,315,511
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression |
EXP |
Chlorogenic Acid results in increased expression of STAR protein |
CTD |
PMID:29899696 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of TJP1 mRNA]; Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of TJP1 protein] |
CTD |
PMID:31390532 |
|
NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
|
|
G |
Tlr3 |
toll-like receptor 3 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of TLR3 protein] |
CTD |
PMID:26079055 |
|
NCBI chr16:50,016,466...50,031,011
Ensembl chr16:50,016,857...50,031,214
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP ISO |
Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TLR4 mRNA]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TLR4 protein] Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of TLR4 protein] |
CTD |
PMID:23146752 PMID:26079055 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO EXP |
Chlorogenic Acid results in increased expression of TNF mRNA Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased expression of TNF mRNA]; Chlorogenic Acid inhibits the reaction [Acetaminophen results in increased secretion of TNF protein]; Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Chlorogenic Acid inhibits the reaction [sodium arsenite results in increased expression of TNF protein] Chlorogenic Acid inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of TNF protein]; Chlorogenic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA] |
CTD |
PMID:21870829 PMID:23146752 PMID:25043994 PMID:26079055 PMID:31306686 PMID:31390532 PMID:33242462 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Chlorogenic Acid inhibits the reaction [Cisplatin results in increased expression of TRP53 protein] |
CTD |
PMID:25043994 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of TPT1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr15:57,891,680...57,894,504
Ensembl chr15:57,891,680...57,894,504
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
Chlorogenic Acid results in increased expression of TXN mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752
|
|
G |
Tyr |
tyrosinase |
increases oxidation multiple interactions |
ISO |
TYR protein results in increased oxidation of Chlorogenic Acid [TYR protein results in increased oxidation of Chlorogenic Acid] which results in decreased abundance of Glutathione |
CTD |
PMID:20685355 |
|
NCBI chr 1:151,012,598...151,106,802
Ensembl chr 1:151,012,598...151,106,802
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
decreases expression |
ISO |
Chlorogenic Acid results in decreased expression of TYRP1 mRNA |
CTD |
PMID:20706672 |
|
NCBI chr 5:98,387,291...98,406,083
Ensembl chr 5:98,387,291...98,406,083
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of Chlorogenic Acid |
CTD |
PMID:15117964 |
|
NCBI chr 9:95,285,592...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a8 |
UDP glucuronosyltransferase family 1 member A8 |
increases glucuronidation |
ISO |
UGT1A8 protein results in increased glucuronidation of Chlorogenic Acid |
CTD |
PMID:15117964 |
|
NCBI chr 9:95,221,474...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
caffeic acid results in increased phosphorylation of and results in decreased activity of ACACA protein |
CTD |
PMID:28576465 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
EXP |
caffeic acid inhibits the reaction [Caffeine results in decreased activity of ACHE protein]; Caffeine promotes the reaction [caffeic acid results in decreased activity of ACHE protein] |
CTD |
PMID:28465162 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Acly |
ATP citrate lyase |
multiple interactions |
ISO |
[Metformin co-treated with caffeic acid] results in decreased expression of ACLY protein |
CTD |
PMID:28576465 |
|
NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions decreases activity |
ISO |
[caffeic acid results in decreased activity of ALOX15 protein] inhibits the reaction [vorinostat results in increased activity of CASP3 protein]; [caffeic acid results in decreased activity of ALOX15 protein] which results in decreased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; [caffeic acid results in decreased activity of ALOX15 protein] which results in increased abundance of 13-hydroxy-9,11-octadecadienoic acid; caffeic acid inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of ALOX15 protein] |
CTD |
PMID:10904086 PMID:11406566 PMID:15574791 |
|
NCBI chr10:56,953,692...56,962,145
Ensembl chr10:56,953,691...56,962,161
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 protein]; caffeic acid inhibits the reaction [Hydrogen Peroxide affects the localization of ALOX5 protein] caffeic acid inhibits the reaction [aluminum chloride results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [aluminum chloride results in increased expression of ALOX5 protein] |
CTD |
PMID:18482095 PMID:18951527 PMID:27368151 |
|
NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [aluminum chloride results in increased expression of APP protein modified form]; caffeic acid inhibits the reaction [aluminum chloride results in increased expression of APP protein] |
CTD |
PMID:18482095 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arg1 |
arginase 1 |
decreases activity |
ISO |
caffeic acid results in decreased activity of ARG1 protein |
CTD |
PMID:27378625 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of ATP6V0D2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 5:33,843,591...33,892,446
Ensembl chr 5:33,843,519...33,892,462
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
[caffeic acid results in decreased activity of ALOX15 protein] inhibits the reaction [vorinostat results in increased activity of CASP3 protein] caffeic acid inhibits the reaction [Valproic Acid results in increased expression of CASP3 protein] |
CTD |
PMID:15574791 PMID:29968957 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions increases activity |
EXP ISO |
caffeic acid inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; caffeic acid inhibits the reaction [Nickel results in decreased activity of CAT protein] caffeic acid results in increased activity of CAT protein caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CAT protein results in increased metabolism of Hydrogen Peroxide]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased activity of CAT protein] |
CTD |
PMID:18405891 PMID:21640567 PMID:22036979 PMID:27378625 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCL2 mRNA; caffeic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein] |
CTD |
PMID:16806235 PMID:31306686 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCL3 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCL4 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCR1 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr 8:132,996,646...133,002,201
Ensembl chr 8:132,996,649...133,002,201
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCR2 mRNA |
CTD |
PMID:16806235 |
|
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CCR4 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr 8:122,530,152...122,535,959
Ensembl chr 8:122,530,624...122,532,070
|
|
G |
Cd4 |
Cd4 molecule |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CD4 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr 4:157,381,862...157,408,357
Ensembl chr 4:157,383,052...157,408,176
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of CD68 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in increased expression of CDC20 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of CDK2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [aluminum chloride results in decreased expression of CHAT protein] |
CTD |
PMID:18482095 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Comt |
catechol-O-methyltransferase |
increases methylation |
ISO |
COMT protein results in increased methylation of caffeic acid |
CTD |
PMID:11160877 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Malathion results in decreased expression of CRH mRNA] |
CTD |
PMID:25404496 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Ctf1 |
cardiotrophin 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of CTF1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:199,162,319...199,168,296
Ensembl chr 1:199,163,086...199,168,296
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased activity of CTSB protein] |
CTD |
PMID:20391626 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol affects the activity of CTSD protein] |
CTD |
PMID:20391626 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of CXCL2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine] |
CTD |
PMID:7710944 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Dap |
death-associated protein |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of DAP mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:84,275,884...84,328,998
Ensembl chr 2:84,275,884...84,328,998
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of DNAJB11 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr11:81,741,342...81,757,806
Ensembl chr11:81,741,297...81,757,813
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of DPYSL4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:211,423,022...211,438,533
Ensembl chr 1:211,423,022...211,438,531
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of EDN1 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
caffeic acid affects the reaction [Acetaminophen results in increased expression of and affects the localization of EGR1 protein]; caffeic acid inhibits the reaction [Acetaminophen results in increased expression of EGR1 mRNA] |
CTD |
PMID:27720869 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Elmo2 |
engulfment and cell motility 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of ELMO2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 3:161,812,474...161,850,006
Ensembl chr 3:161,812,474...162,003,588
|
|
G |
Erf |
Ets2 repressor factor |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of ERF mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:82,112,449...82,120,902
Ensembl chr 1:82,112,449...82,120,902
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of F3 protein] |
CTD |
PMID:27720869 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fasn |
fatty acid synthase |
decreases expression multiple interactions |
ISO |
caffeic acid results in decreased expression of FASN mRNA [Metformin co-treated with caffeic acid] results in decreased expression of FASN protein |
CTD |
PMID:21870829 PMID:28576465 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Flrt2 |
fibronectin leucine rich transmembrane protein 2 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of FLRT2 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 6:119,518,459...119,613,534
Ensembl chr 6:119,519,714...119,609,296
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of FLT4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr10:35,078,782...35,120,296
Ensembl chr10:35,078,726...35,121,599
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
ISO |
caffeic acid results in decreased activity of G6PD protein |
CTD |
PMID:25130191 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of GADD45A mRNA]; caffeic acid inhibits the reaction [Acetaminophen results in increased expression of GADD45A protein] |
CTD |
PMID:27720869 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol affects the activity of GLB1 protein] |
CTD |
PMID:20391626 |
|
NCBI chr 8:122,439,328...122,511,939
Ensembl chr 8:122,439,328...122,511,939
|
|
G |
Gls |
glutaminase |
increases expression |
ISO |
caffeic acid results in increased expression of GLS protein |
CTD |
PMID:28576465 |
|
NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GOT1 protein] |
CTD |
PMID:15212457 |
|
NCBI chr 1:263,246,248...263,269,762
Ensembl chr 1:263,246,248...263,269,762
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GPT protein] caffeic acid inhibits the reaction [Acetaminophen results in increased activity of GPT protein] |
CTD |
PMID:15212457 PMID:27720869 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [Cisplatin results in decreased activity of GSR protein] caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased activity of GSR protein] caffeic acid promotes the reaction [Thapsigargin results in decreased expression of GSR mRNA] |
CTD |
PMID:19442820 PMID:21640567 PMID:22036979 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases activity |
EXP |
caffeic acid results in decreased activity of GSTM1 protein |
CTD |
PMID:8340025 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases activity |
EXP |
caffeic acid results in decreased activity of GSTM2 protein |
CTD |
PMID:8340025 |
|
NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases activity |
EXP |
caffeic acid results in decreased activity of GSTP1 protein |
CTD |
PMID:8340025 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:20391626 |
|
NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
|
|
G |
H6pd |
hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Cisplatin results in decreased activity of H6PD protein] |
CTD |
PMID:21640567 |
|
NCBI chr 5:166,994,683...167,030,441
Ensembl chr 5:166,998,881...167,030,441
|
|
G |
Havcr2 |
hepatitis A virus cellular receptor 2 |
multiple interactions |
ISO |
[resveratrol co-treated with Catechin co-treated with caffeic acid] results in decreased expression of HAVCR2 mRNA |
CTD |
PMID:16806235 |
|
NCBI chr10:31,561,838...31,590,624
Ensembl chr10:31,561,895...31,588,943
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of HES1 mRNA] |
CTD |
PMID:29968957 |
|
NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
caffeic acid results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:34,357,372...34,537,798
Ensembl chr11:34,352,287...34,526,931
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
ISO |
caffeic acid results in decreased expression of HMGCR mRNA |
CTD |
PMID:21870829 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of HSP90B1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 7:27,226,570...27,240,533
Ensembl chr 7:27,226,569...27,240,533
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of HSPE1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 9:61,691,246...61,724,948
Ensembl chr 9:61,692,154...61,694,599
|
|
G |
Ifng |
interferon gamma |
increases expression multiple interactions |
ISO EXP |
caffeic acid results in increased expression of IFNG protein caffeic acid inhibits the reaction [Valproic Acid results in increased expression of IFNG protein] |
CTD |
PMID:27378625 PMID:29968957 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
caffeic acid results in decreased expression of IL10 protein |
CTD |
PMID:27378625 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of IL1B protein] caffeic acid inhibits the reaction [Aluminum results in increased expression of IL1B protein] |
CTD |
PMID:27368151 PMID:27720869 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
caffeic acid results in increased expression of IL2 protein |
CTD |
PMID:27378625 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il21r |
interleukin 21 receptor |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of IL21R mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:196,996,405...197,024,185
Ensembl chr 1:196,996,581...197,024,166
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
caffeic acid results in decreased expression of IL4 protein |
CTD |
PMID:27378625 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
caffeic acid results in increased expression of IL6 mRNA caffeic acid inhibits the reaction [Acetaminophen results in increased expression of IL6 protein] caffeic acid inhibits the reaction [Aluminum results in increased expression of IL6 protein] |
CTD |
PMID:21870829 PMID:27368151 PMID:27720869 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Kif15 |
kinesin family member 15 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in increased expression of KIF15 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 8:132,033,117...132,103,528
Ensembl chr 8:132,032,944...132,103,927
|
|
G |
Kif20b |
kinesin family member 20B |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of KIF20B mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:253,220,038...253,275,523
Ensembl chr 1:253,221,812...253,275,490
|
|
G |
Kif2c |
kinesin family member 2C |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Thapsigargin results in increased expression of KIF2C mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 5:136,027,923...136,053,268
Ensembl chr 5:136,027,934...136,053,210
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased expression of LDHA protein] |
CTD |
PMID:21472895 |
|
NCBI chr 1:102,900,288...102,909,713
Ensembl chr 1:102,900,286...102,909,707
|
|
G |
Ldhb |
lactate dehydrogenase B |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Isoproterenol results in increased expression of LDHB protein] |
CTD |
PMID:21472895 |
|
NCBI chr 4:176,701,980...176,719,999
Ensembl chr 4:176,701,983...176,720,012
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
caffeic acid results in decreased activity of MAOA protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
caffeic acid results in decreased activity of MAOB protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,430,694...6,533,520
Ensembl chr X:6,430,594...6,533,534
|
|
G |
Map2k5 |
mitogen activated protein kinase kinase 5 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in decreased expression of MAP2K5 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 8:68,055,976...68,282,656
Ensembl chr 8:68,055,972...68,282,590
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:27720869 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:27720869 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of MFN1 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:118,929,738...118,971,689
Ensembl chr 2:118,929,738...118,973,698
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases activity |
EXP |
caffeic acid results in increased activity of MGST1 protein |
CTD |
PMID:16125204 |
|
NCBI chr 4:172,119,382...172,134,609
Ensembl chr 4:172,119,331...172,134,607
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases activity |
ISO EXP |
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [MPO protein results in increased metabolism of Hydrogen Peroxide]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MPO protein] caffeic acid inhibits the reaction [Ethanol results in increased activity of MPO protein]; NG-Nitroarginine Methyl Ester inhibits the reaction [caffeic acid inhibits the reaction [Ethanol results in increased activity of MPO protein]] caffeic acid results in decreased activity of MPO protein |
CTD |
PMID:22036979 PMID:24060682 PMID:33301711 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mrpl45 |
mitochondrial ribosomal protein L45 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of MRPL45 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr10:85,257,876...85,269,806
Ensembl chr10:85,257,876...85,269,806
|
|
G |
Mrrf |
mitochondrial ribosome recycling factor |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of MRRF mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 3:15,463,884...15,520,621
Ensembl chr 3:15,463,953...15,520,618
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
[caffeic acid co-treated with Zymosan] results in increased expression of COX2 protein; caffeic acid inhibits the reaction [Zymosan results in increased expression of COX2 protein] |
CTD |
PMID:30481570 |
|
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Ndp |
norrin cystine knot growth factor NDP |
increases expression |
ISO |
caffeic acid results in increased expression of NDP mRNA |
CTD |
PMID:19442820 |
|
NCBI chr X:6,791,090...6,815,586
Ensembl chr X:6,791,136...6,815,583 Ensembl chr X:6,791,136...6,815,583
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of NOS2 protein] caffeic acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:29968957 PMID:31306686 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
ISO |
caffeic acid results in increased expression of NOS3 mRNA |
CTD |
PMID:15740983 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of NOTCH1 mRNA] |
CTD |
PMID:29968957 |
|
NCBI chr 3:3,905,562...3,951,015
Ensembl chr 3:3,905,453...3,951,025
|
|
G |
Nt5e |
5' nucleotidase, ecto |
multiple interactions decreases activity |
EXP |
caffeic acid inhibits the reaction [Caffeine results in decreased activity of NT5E protein]; Caffeine promotes the reaction [caffeic acid results in decreased activity of NT5E protein] |
CTD |
PMID:28465162 |
|
NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696
|
|
G |
Pdcd10 |
programmed cell death 10 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PDCD10 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:173,966,701...174,012,730
Ensembl chr 2:173,967,080...174,012,676
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
ISO |
caffeic acid results in decreased activity of PGD protein |
CTD |
PMID:25130191 |
|
NCBI chr 5:165,966,128...165,982,327
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
ISO |
caffeic acid results in increased expression of PIK3R1 mRNA |
CTD |
PMID:21870829 |
|
NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
|
|
G |
Plk1 |
polo-like kinase 1 |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in increased expression of PLK1 mRNA |
CTD |
PMID:19442820 |
|
NCBI chr 1:192,115,990...192,125,969
Ensembl chr 1:192,115,966...192,125,989
|
|
G |
Plk4 |
polo-like kinase 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of PLK4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:127,686,911...127,705,518
Ensembl chr 2:127,686,925...127,705,518
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
caffeic acid results in increased expression of PPARG mRNA |
CTD |
PMID:21870829 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Prdx5 |
peroxiredoxin 5 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PRDX5 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:222,164,462...222,167,447
Ensembl chr 1:222,164,462...222,167,447
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PTGS2 mRNA] |
CTD |
PMID:19442820 PMID:22036979 PMID:31306686 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptx3 |
pentraxin 3 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of PTX3 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 2:158,097,843...158,103,653
Ensembl chr 2:158,097,843...158,103,653
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:27720869 |
|
NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
caffeic acid inhibits the reaction [Valproic Acid results in increased expression of RELA protein] |
CTD |
PMID:29968957 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Metformin co-treated with caffeic acid] results in decreased expression of SCD1 protein |
CTD |
PMID:28576465 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Acetaminophen results in increased expression of SERPINE1 protein] |
CTD |
PMID:27720869 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sfxn4 |
sideroflexin 4 |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in decreased expression of SFXN4 mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 1:282,213,610...282,236,851
Ensembl chr 1:282,213,675...282,235,974
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
caffeic acid results in increased expression of SLC2A4 mRNA |
CTD |
PMID:21870829 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [SNCA protein binds to SNCA protein] |
CTD |
PMID:20150427 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Metformin co-treated with caffeic acid] results in decreased expression of SREBF1 protein |
CTD |
PMID:28576465 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Stk32a |
serine/threonine kinase 32A |
multiple interactions |
ISO |
[Thapsigargin co-treated with caffeic acid] results in decreased expression of STK32A mRNA |
CTD |
PMID:19442820 |
|
NCBI chr18:37,597,305...37,706,884
Ensembl chr18:37,597,156...37,710,306
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation |
ISO |
SULT1A1 protein results in increased sulfation of caffeic acid |
CTD |
PMID:17433394 |
|
NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
|
|
G |
Sult1c2a |
sulfotransferase family, cytosolic, 1C, member 2a |
increases sulfation |
ISO |
SULT1C2 protein results in increased sulfation of caffeic acid |
CTD |
PMID:17433394 |
|
NCBI chr 9:4,152,588...4,168,355
Ensembl chr 9:4,152,589...4,168,221
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO EXP |
caffeic acid results in increased expression of TNF mRNA caffeic acid inhibits the reaction [Aluminum results in increased expression of TNF protein]; caffeic acid inhibits the reaction [Valproic Acid results in increased expression of TNF protein] caffeic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TNF protein] |
CTD |
PMID:21870829 PMID:22036979 PMID:27368151 PMID:29968957 PMID:31306686 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
affects expression multiple interactions |
ISO |
caffeic acid affects the expression of TP53 protein caffeic acid promotes the reaction [Thapsigargin results in decreased expression of TP53 mRNA] |
CTD |
PMID:11522280 PMID:19442820 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tyr |
tyrosinase |
increases oxidation multiple interactions |
ISO |
TYR protein results in increased oxidation of caffeic acid [TYR protein results in increased oxidation of caffeic acid] which results in decreased abundance of Glutathione |
CTD |
PMID:20685355 |
|
NCBI chr 1:151,012,598...151,106,802
Ensembl chr 1:151,012,598...151,106,802
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
multiple interactions |
ISO |
caffeic acid promotes the reaction [Thapsigargin results in increased expression of UBE2C mRNA] |
CTD |
PMID:19442820 |
|
NCBI chr 3:161,236,971...161,239,371
Ensembl chr 3:161,236,898...161,241,159
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of caffeic acid |
CTD |
PMID:15117964 |
|
NCBI chr 9:95,285,592...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a8 |
UDP glucuronosyltransferase family 1 member A8 |
increases glucuronidation |
ISO |
UGT1A8 protein results in increased glucuronidation of caffeic acid |
CTD |
PMID:15117964 |
|
NCBI chr 9:95,221,474...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases secretion |
ISO |
caffeic acid results in decreased secretion of VEGFA protein |
CTD |
PMID:27378625 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [XDH protein results in increased chemical synthesis of Uric Acid]]; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of XDH protein] |
CTD |
PMID:22036979 |
|
NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
ethyl caffeate affects the phosphorylation of and affects the activity of AKT1 protein |
CTD |
PMID:24892518 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Cdh2 |
cadherin 2 |
affects expression |
ISO |
ethyl caffeate affects the expression of CDH2 protein |
CTD |
PMID:24892518 |
|
NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
affects expression |
ISO |
ethyl caffeate affects the expression of CDK2 protein |
CTD |
PMID:24892518 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
affects expression |
ISO |
ethyl caffeate affects the expression of CDK4 protein |
CTD |
PMID:24892518 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
affects expression multiple interactions |
ISO |
ethyl caffeate affects the expression of ERBB2 protein ethyl caffeate affects the phosphorylation of and affects the activity of ERBB2 protein |
CTD |
PMID:24892518 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
affects expression |
ISO |
ethyl caffeate affects the expression of FGFR1 protein |
CTD |
PMID:24892518 |
|
NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
|
|
G |
Ilk |
integrin-linked kinase |
affects expression |
ISO |
ethyl caffeate affects the expression of ILK protein |
CTD |
PMID:24892518 |
|
NCBI chr 1:170,578,941...170,585,192
Ensembl chr 1:170,578,889...170,585,189
|
|
G |
Itga3 |
integrin subunit alpha 3 |
multiple interactions |
ISO |
ethyl caffeate affects the expression of [ITGA3 protein binds to ITGB1 protein] |
CTD |
PMID:24892518 |
|
NCBI chr10:82,855,841...82,887,755
Ensembl chr10:82,855,613...82,887,497
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
ethyl caffeate affects the expression of [ITGA3 protein binds to ITGB1 protein] |
CTD |
PMID:24892518 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Kdr |
kinase insert domain receptor |
affects expression |
ISO |
ethyl caffeate affects the expression of KDR protein |
CTD |
PMID:24892518 |
|
NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
ethyl caffeate affects the phosphorylation of and affects the activity of MAPK1 protein |
CTD |
PMID:24892518 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
ethyl caffeate affects the phosphorylation of and affects the activity of MAPK3 protein |
CTD |
PMID:24892518 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
affects phosphorylation |
ISO |
ethyl caffeate affects the phosphorylation of RB1 protein |
CTD |
PMID:24892518 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
methyl caffeate analog results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:25481497 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
methyl caffeate results in increased expression of BAX protein |
CTD |
PMID:26415618 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
methyl caffeate binds to and results in decreased expression of BCL2 protein |
CTD |
PMID:26415618 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
methyl caffeate results in increased expression of BID protein |
CTD |
PMID:26415618 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
methyl caffeate results in increased activity of CASP3 protein |
CTD |
PMID:26415618 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
methyl caffeate analog results in increased expression of CDKN1A protein |
CTD |
PMID:25481497 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Kdr |
kinase insert domain receptor |
decreases expression |
ISO |
methyl caffeate analog results in decreased expression of KDR protein |
CTD |
PMID:25481497 |
|
NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
methyl caffeate analog results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:25481497 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
methyl caffeate analog results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:25481497 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
affects binding |
ISO |
methyl caffeate binds to MDM2 protein |
CTD |
PMID:26415618 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
methyl caffeate analog results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:25481497 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
methyl caffeate analog results in decreased expression of and results in decreased activity of MMP9 protein |
CTD |
PMID:25481497 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
methyl caffeate analog results in decreased phosphorylation of MTOR protein |
CTD |
PMID:25481497 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
methyl caffeate binds to and results in increased activity of PARP1 protein |
CTD |
PMID:26415618 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
methyl caffeate analog results in increased expression of TP53 protein |
CTD |
PMID:25481497 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
methyl caffeate analog results in decreased expression of and results in decreased secretion of VEGFA protein |
CTD |
PMID:25481497 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
A2m |
alpha-2-macroglobulin |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of A2M mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 4:154,309,426...154,359,138
Ensembl chr 4:154,309,426...154,359,137 Ensembl chr 4:154,309,426...154,359,137
|
|
G |
Aanat |
aralkylamine N-acetyltransferase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AANAT mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:105,568,091...105,572,407
Ensembl chr10:105,568,091...105,572,403
|
|
G |
Abca5 |
ATP binding cassette subfamily A member 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ABCA5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:98,573,226...98,645,028
Ensembl chr10:98,576,039...98,644,938
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
caffeic acid phenethyl ester metabolite results in decreased activity of ABCC1 protein |
CTD |
PMID:15885658 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ABCC3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Acan |
aggrecan |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ACAN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:140,762,758...140,824,441
Ensembl chr 1:140,762,758...140,824,441
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ACOT2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:107,460,596...107,468,324
Ensembl chr 6:107,460,668...107,467,487
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein] |
CTD |
PMID:28363435 |
|
NCBI chr 8:23,142,733...23,149,067
Ensembl chr 8:23,142,734...23,148,396
|
|
G |
Ada |
adenosine deaminase |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Methotrexate results in increased activity of ADA protein] |
CTD |
PMID:16325979 |
|
NCBI chr 3:160,115,840...160,139,947
Ensembl chr 3:160,115,842...160,139,947
|
|
G |
Adam7 |
ADAM metallopeptidase domain 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ADAM7 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr15:49,418,946...49,467,174
Ensembl chr15:49,418,946...49,467,174
|
|
G |
Adcy2 |
adenylate cyclase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ADCY2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:37,043,071...37,698,390
Ensembl chr 1:37,507,276...37,698,390
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ADRA1D mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:124,129,558...124,145,566
Ensembl chr 3:124,129,558...124,145,566
|
|
G |
Agap2 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AGAP2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:70,360,199...70,377,422
Ensembl chr 7:70,364,813...70,377,422
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
caffeic acid phenethyl ester promotes the reaction [Nitrogen Mustard Compounds results in decreased expression of AHR protein] |
CTD |
PMID:17204746 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Aimp1 |
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [AIMP1 protein results in increased expression of IL12B mRNA] |
CTD |
PMID:16365417 |
|
NCBI chr 2:237,727,782...237,751,327
Ensembl chr 2:237,727,764...237,751,378
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AKAP9 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:27,195,346...27,331,582
Ensembl chr 4:27,195,346...27,331,582
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
decreases activity |
ISO |
caffeic acid phenethyl ester results in decreased activity of AKR1B1 protein |
CTD |
PMID:27163852 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
decreases activity |
ISO |
caffeic acid phenethyl ester results in decreased activity of AKR1B10 protein |
CTD |
PMID:27163852 |
|
NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity |
ISO |
caffeic acid phenethyl ester results in decreased activity of AKR1C4 protein |
CTD |
PMID:27163852 |
|
NCBI chr17:69,441,253...69,460,334
Ensembl chr17:69,441,223...69,460,321
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases activity |
ISO |
caffeic acid phenethyl ester results in decreased activity of AKR1C2 protein |
CTD |
PMID:27163852 |
|
NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
caffeic acid phenethyl ester results in decreased activity of AKR1C3 protein |
CTD |
PMID:27163852 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation |
ISO |
caffeic acid phenethyl ester analog affects the phosphorylation of AKT1 protein |
CTD |
PMID:32125059 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO EXP |
caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in increased activity of ALPL protein] caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in decreased expression of ALPL protein] |
CTD |
PMID:18436364 PMID:28363435 |
|
NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
|
|
G |
Ankrd17 |
ankyrin repeat domain 17 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of ANKRD17 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr14:19,291,025...19,431,521
Ensembl chr14:19,318,565...19,431,515
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ARRB1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ATF6 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ATF6 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of ATOX1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr10:40,790,850...40,805,886
Ensembl chr10:40,790,845...40,805,941
|
|
G |
Axl |
Axl receptor tyrosine kinase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AXL mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with caffeic acid phenethyl ester] results in increased expression of BAX mRNA |
CTD |
PMID:24289642 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
decreases phosphorylation |
ISO |
caffeic acid phenethyl ester results in decreased phosphorylation of BCAR1 protein |
CTD |
PMID:10741720 |
|
NCBI chr19:43,932,543...43,967,452
Ensembl chr19:43,932,554...43,955,783
|
|
G |
Bgn |
biglycan |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of BGN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr X:157,319,042...157,331,204
Ensembl chr X:157,319,046...157,331,204
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of BIRC2 protein |
CTD |
PMID:15291876 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of BIRC3 protein |
CTD |
PMID:15291876 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Ca3 |
carbonic anhydrase 3 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CAR3 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 2:88,126,519...88,136,063
Ensembl chr 2:88,126,667...88,135,410
|
|
G |
Ca4 |
carbonic anhydrase 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CAR4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:72,272,286...72,281,069
Ensembl chr10:72,272,248...72,281,067
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CACNA1A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr19:25,453,236...25,749,550
Ensembl chr19:25,526,751...25,749,550
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CACNA1H mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:14,730,932...14,789,201
Ensembl chr10:14,730,941...14,788,617
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CAMK2D mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:230,900,907...231,132,207
Ensembl chr 2:230,901,126...231,132,039
|
|
G |
Capn8 |
calpain 8 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CAPN8 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr13:100,980,149...101,043,110
Ensembl chr13:100,980,574...101,043,110
|
|
G |
Casp1 |
caspase 1 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of CASP1 protein |
CTD |
PMID:15469948 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
decreases activity increases activity multiple interactions |
EXP ISO |
caffeic acid phenethyl ester results in decreased activity of CASP3 protein caffeic acid phenethyl ester analog results in increased activity of CASP3 protein caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in increased activity of CASP3 protein] caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein] |
CTD |
PMID:15469948 PMID:18436364 PMID:28363435 PMID:32125059 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP8 protein] |
CTD |
PMID:18436364 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
caffeic acid phenethyl ester inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; caffeic acid phenethyl ester promotes the reaction [Doxorubicin results in increased activity of CAT protein] caffeic acid phenethyl ester inhibits the reaction [Bleomycin results in decreased expression of CAT protein]; caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:14745846 PMID:15369732 PMID:18436364 PMID:23570914 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of CCL2 mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CCL5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of CCNB1 protein |
CTD |
PMID:16085347 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with caffeic acid phenethyl ester] results in decreased expression of CCND1 mRNA; caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein] |
CTD |
PMID:20420878 PMID:24289642 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
EXP ISO |
caffeic acid phenethyl ester inhibits the reaction [CDK2 protein binds to CCNE1 protein] [Tretinoin co-treated with caffeic acid phenethyl ester] inhibits the reaction [CDK2 protein binds to CCNE1 protein] |
CTD |
PMID:15885897 PMID:16766008 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions increases expression |
EXP ISO |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CD14 mRNA caffeic acid phenethyl ester promotes the reaction [Tretinoin results in increased expression of CD14 protein] caffeic acid phenethyl ester results in increased expression of CD14 protein |
CTD |
PMID:16766008 PMID:20360939 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CD151 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:214,446,659...214,450,668
Ensembl chr 1:214,009,784...214,013,765 Ensembl chr 1:214,009,784...214,013,765
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CD86 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of CDK1 protein |
CTD |
PMID:16085347 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
EXP ISO |
caffeic acid phenethyl ester inhibits the reaction [CDK2 protein binds to CCNE1 protein] [Tretinoin co-treated with caffeic acid phenethyl ester] inhibits the reaction [CDK2 protein binds to CCNE1 protein] |
CTD |
PMID:15885897 PMID:16766008 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO EXP |
caffeic acid phenethyl ester results in increased expression of CDKN1A protein [Benzo(a)pyrene co-treated with caffeic acid phenethyl ester] results in increased expression of CDKN1A mRNA; caffeic acid phenethyl ester inhibits the reaction [Folic Acid results in increased expression of CDKN1A protein]; Tretinoin promotes the reaction [caffeic acid phenethyl ester results in increased expression of CDKN1A protein] |
CTD |
PMID:15885897 PMID:16766008 PMID:24289642 PMID:26056802 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
EXP ISO |
caffeic acid phenethyl ester results in increased expression of CDKN1B protein caffeic acid phenethyl ester inhibits the reaction [Folic Acid results in increased expression of CDKN1B protein] |
CTD |
PMID:15885897 PMID:26056802 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression multiple interactions |
EXP |
caffeic acid phenethyl ester results in increased expression of CDKN2A protein caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA] |
CTD |
PMID:15885897 PMID:20360939 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CDKN2C mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:129,347,731...129,352,886
Ensembl chr 5:129,347,732...129,352,886
|
|
G |
Ceacam4 |
CEA cell adhesion molecule 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of CEACAM10 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:81,643,809...81,650,085
Ensembl chr 1:81,643,816...81,650,094 Ensembl chr 1:81,643,816...81,650,094
|
|
G |
Cebpe |
CCAAT/enhancer binding protein epsilon |
multiple interactions increases expression |
ISO |
Tretinoin promotes the reaction [caffeic acid phenethyl ester results in increased expression of CEBPE protein] |
CTD |
PMID:16766008 |
|
NCBI chr15:33,356,119...33,357,517
Ensembl chr15:33,355,947...33,358,138
|
|
G |
Cers2 |
ceramide synthase 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 2:196,487,656...196,495,930
Ensembl chr 2:196,487,656...196,496,986
|
|
G |
Cers4 |
ceramide synthase 4 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS4 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS4 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS4 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr12:4,439,750...4,474,759
Ensembl chr12:4,439,750...4,474,729
|
|
G |
Cgm4 |
carcinoembryonic antigen gene family 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CGM4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:79,030,291...79,043,259
Ensembl chr 1:79,030,291...79,080,881
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CHRNA2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr15:42,808,897...42,825,179
Ensembl chr15:42,808,897...42,825,179
|
|
G |
Chrne |
cholinergic receptor nicotinic epsilon subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of CHRNE mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:57,238,960...57,246,750
Ensembl chr10:57,238,946...57,243,435
|
|
G |
Clcn1 |
chloride voltage-gated channel 1 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of CLCN1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 4:71,674,218...71,704,318
Ensembl chr 4:71,675,383...71,702,819
|
|
G |
Cldn2 |
claudin 2 |
decreases expression multiple interactions |
ISO |
caffeic acid phenethyl ester results in decreased expression of CLDN2 mRNA; caffeic acid phenethyl ester results in decreased expression of CLDN2 protein Cantharidin inhibits the reaction [caffeic acid phenethyl ester results in decreased expression of CLDN2 protein]; Chloroquine inhibits the reaction [caffeic acid phenethyl ester results in decreased expression of CLDN2 protein]; CLDN2 protein inhibits the reaction [caffeic acid phenethyl ester results in increased susceptibility to and results in increased activity of Doxorubicin] |
CTD |
PMID:29597147 |
|
NCBI chr X:111,122,552...111,133,188
Ensembl chr X:111,122,552...111,137,769
|
|
G |
Cldn7 |
claudin 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CLDN7 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:56,576,326...56,578,632
Ensembl chr10:56,576,428...56,578,626
|
|
G |
Clic5 |
chloride intracellular channel 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CLIC5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 9:19,121,676...19,372,673
Ensembl chr 9:19,121,677...19,372,673
|
|
G |
Clock |
clock circadian regulator |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CLOCK mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:34,418,226...34,502,218
Ensembl chr14:34,446,616...34,502,218
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
increases expression |
ISO |
caffeic acid phenethyl ester results in increased expression of COL18A1 protein |
CTD |
PMID:20433813 |
|
NCBI chr20:12,225,202...12,332,858
Ensembl chr20:12,225,202...12,332,858
|
|
G |
Cox4i2 |
cytochrome c oxidase subunit 4i2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of COX4I2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:148,234,546...148,245,424
Ensembl chr 3:148,234,193...148,245,416
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of COX6A2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:199,624,037...199,626,255
Ensembl chr 1:199,624,037...199,624,783
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of COX7A2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 8:87,209,529...87,213,627
Ensembl chr 8:87,209,530...87,213,627
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CRMP1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:78,266,931...78,312,777
Ensembl chr14:78,266,931...78,308,933
|
|
G |
Cs |
citrate synthase |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased activity of CS protein; [caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of CS mRNA; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased activity of CS protein]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of CS mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 7:2,752,680...2,778,963
Ensembl chr 7:2,752,680...2,778,963
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CSK mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:62,405,714...62,424,707
Ensembl chr 8:62,405,715...62,424,303
|
|
G |
Cspg4 |
chondroitin sulfate proteoglycan 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CSPG4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:61,532,465...61,567,510
Ensembl chr 8:61,532,465...61,567,510
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of CTNNB1 protein |
CTD |
PMID:10783313 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CTSK mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CXCR3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr X:71,614,346...71,616,997
Ensembl chr X:71,614,346...71,616,997
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CYB5A mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of CYBA mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Calcium results in increased secretion of CYCS protein] |
CTD |
PMID:15469948 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases expression |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CYP1A2 mRNA caffeic acid phenethyl ester results in decreased expression of CYP1A2 protein |
CTD |
PMID:20360939 PMID:22291063 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2a2 |
cytochrome P450, family 2, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CYP2A2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:83,744,229...83,766,490
Ensembl chr 1:83,653,234...83,766,484
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions decreases expression |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CYP2B1 mRNA caffeic acid phenethyl ester results in decreased expression of CYP2B1 protein |
CTD |
PMID:20360939 PMID:22291063 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of CYP2B2 protein |
CTD |
PMID:22291063 |
|
NCBI chr 1:83,103,925...83,119,578
Ensembl chr 1:83,103,925...83,119,193
|
|
G |
Cyp2c13 |
cytochrome P450, family 2, subfamily c, polypeptide 13 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CYP2C13 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:258,796,624...258,877,023
Ensembl chr 1:258,796,622...258,877,045
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP ISO |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of CYP2E1 mRNA caffeic acid phenethyl ester inhibits the reaction [CYP2E1 protein results in increased hydroxylation of aniline] |
CTD |
PMID:18436364 PMID:20360939 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a18 |
cytochrome P450, family 3, subfamily a, polypeptide 18 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of CYP3A18 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr12:10,636,294...10,684,273
Ensembl chr12:10,636,275...10,684,278
|
|
G |
Cyth2 |
cytohesin 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of CYTH2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:101,796,349...101,803,407
Ensembl chr 1:101,796,349...101,803,200
|
|
G |
Dbn1 |
drebrin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DBN1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr17:9,679,511...9,693,878
Ensembl chr17:9,679,628...9,693,820
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DDIT3 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DDIT3 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DDIT3 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Deaf1 |
DEAF1 transcription factor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of DEAF1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:214,283,787...214,317,466
Ensembl chr 1:214,283,790...214,317,466
|
|
G |
Degs1 |
delta(4)-desaturase, sphingolipid 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DEGS1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr13:100,665,265...100,672,731
Ensembl chr13:100,666,075...100,672,731
|
|
G |
Degs2 |
delta(4)-desaturase, sphingolipid 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DEGS2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DEGS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DEGS2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 6:132,591,968...132,608,600
Ensembl chr 6:132,591,969...132,608,600
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DGKB mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:57,516,351...58,277,385
Ensembl chr 6:57,516,713...58,277,279
|
|
G |
Dhfr |
dihydrofolate reductase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DHFR mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:21,931,887...21,958,927
Ensembl chr 2:21,931,493...21,962,453
|
|
G |
Disc1 |
DISC1 scaffold protein |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of DISC1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr19:57,818,838...58,069,992
Ensembl chr19:57,820,260...58,066,152
|
|
G |
Dmrt1 |
doublesex and mab-3 related transcription factor 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DMRT1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:243,477,403...243,582,629
Ensembl chr 1:243,477,493...243,582,629
|
|
G |
Dnah10 |
dynein, axonemal, heavy chain 10 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DNAH10 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr12:37,237,482...37,365,258
|
|
G |
Dnah5 |
dynein, axonemal, heavy chain 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DNAH5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:80,947,730...81,143,997 NCBI chr 2:81,159,060...81,337,560
Ensembl chr 2:80,948,658...81,143,447
|
|
G |
Dpys |
dihydropyrimidinase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of DPYS mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:78,769,918...78,847,941
Ensembl chr 7:78,769,807...78,847,974
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of DUSP6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:41,475,163...41,479,393
Ensembl chr 7:41,475,163...41,479,392
|
|
G |
E2f6 |
E2F transcription factor 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of E2F6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:42,092,513...42,108,692
Ensembl chr 6:42,092,467...42,108,702
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ECHS1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:212,570,213...212,579,040
Ensembl chr 1:212,570,195...212,579,057 Ensembl chr 1:212,570,195...212,579,057
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Oxygen deficiency results in increased expression of EDN1 mRNA]; caffeic acid phenethyl ester inhibits the reaction [Oxygen deficiency results in increased expression of EDN1 protein] |
CTD |
PMID:21926265 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ETS1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:33,756,634...33,879,625
Ensembl chr 8:33,816,386...33,879,625
|
|
G |
Fabp7 |
fatty acid binding protein 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FABP7 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr20:40,769,624...40,773,156
Ensembl chr20:40,769,586...40,773,349
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in increased expression of FAS protein] |
CTD |
PMID:18436364 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Carbon Tetrachloride results in increased expression of FASL protein] |
CTD |
PMID:18436364 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of FGF15 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of FGF15 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 1:218,058,405...218,061,693
Ensembl chr 1:218,058,405...218,061,693
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FGF7 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
|
|
G |
Fgg |
fibrinogen gamma chain |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of FGG mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:181,987,080...181,994,523
Ensembl chr 2:181,987,217...181,994,514
|
|
G |
Fmo2 |
flavin containing dimethylaniline monoxygenase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FMO2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr13:80,752,526...80,775,264
Ensembl chr13:80,755,058...80,775,264
|
|
G |
Foxc2 |
forkhead box C2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FOXC2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr19:53,044,379...53,047,081
Ensembl chr19:53,044,379...53,047,081
|
|
G |
Foxd1 |
forkhead box D1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FOXD1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:28,460,068...28,462,488
Ensembl chr 2:28,460,068...28,462,488
|
|
G |
Frmd6 |
FERM domain containing 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FRMD6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:93,281,382...93,358,888
Ensembl chr 6:93,281,408...93,358,840
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FTL mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Fut2 |
fucosyltransferase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of FUT2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:101,631,633...101,651,668
Ensembl chr 1:101,631,635...101,651,668
|
|
G |
Gas6 |
growth arrest specific 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GAS6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr16:81,213,364...81,243,824
Ensembl chr16:81,213,364...81,243,757
|
|
G |
Gc |
GC, vitamin D binding protein |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GC mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:20,267,023...20,302,577
Ensembl chr14:20,266,891...20,302,581
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of GCH1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr15:23,935,011...23,968,971
Ensembl chr15:23,934,585...23,969,011
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Bleomycin results in decreased expression of GCLC protein] |
CTD |
PMID:23570914 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GDNF mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions increases expression |
EXP |
NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of GFAP protein] |
CTD |
PMID:20836997 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Gfer |
growth factor, augmenter of liver regeneration |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GFER mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:14,059,347...14,061,703
Ensembl chr10:14,059,347...14,061,703
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:123,573,394...123,582,431
Ensembl chr 3:123,578,997...123,581,518
|
|
G |
Ghr |
growth hormone receptor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of GHR mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:53,149,225...53,413,954
Ensembl chr 2:53,150,370...53,413,638
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [GJB1 protein results in decreased expression of IL1B mRNA]; caffeic acid phenethyl ester inhibits the reaction [GJB1 protein results in decreased expression of IL1B protein] |
CTD |
PMID:15350541 |
|
NCBI chr X:71,272,030...71,279,973
Ensembl chr X:71,272,042...71,279,977
|
|
G |
Gjc2 |
gap junction protein, gamma 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GJC2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:45,526,740...45,535,520
Ensembl chr10:45,526,745...45,534,570
|
|
G |
Gls |
glutaminase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GLS mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
|
|
G |
Gnal |
G protein subunit alpha L |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GNAL mRNA |
CTD |
PMID:20360939 |
|
NCBI chr18:62,805,406...62,946,133
Ensembl chr18:62,805,410...62,944,630
|
|
G |
Golga2 |
golgin A2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GOLGA2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:11,317,328...11,337,569
Ensembl chr 3:11,317,183...11,336,458
|
|
G |
Gpr19 |
G protein-coupled receptor 19 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GPR19 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:168,639,930...168,668,345
Ensembl chr 4:168,639,940...168,656,673
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of GRIK2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr20:53,791,428...54,517,691
Ensembl chr20:53,789,760...54,517,709
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GRIK5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:81,885,516...81,946,731
Ensembl chr 1:81,885,521...81,946,714
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of GSR mRNA |
CTD |
PMID:20360939 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of GSTK1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 4:71,621,777...71,626,096
Ensembl chr 4:71,621,729...71,626,107
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of GSTP1 protein |
CTD |
PMID:17106925 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstt2 |
glutathione S-transferase, theta 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of GSTT2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr20:13,760,810...13,764,481
Ensembl chr20:13,760,810...13,764,475
|
|
G |
Gyg1 |
glycogenin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of GYG1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:104,916,734...104,958,219
Ensembl chr 2:104,916,738...104,958,034
|
|
G |
H2ac1 |
H2A clustered histone 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of H2AC1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr17:43,422,454...43,422,846
Ensembl chr17:43,422,454...43,422,846
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of HAMP mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hdgf |
heparin binding growth factor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of HDGF mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:187,274,898...187,284,670
Ensembl chr 2:187,275,120...187,284,281
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of HMGCS2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
caffeic acid phenethyl ester results in increased expression of HMOX1 protein caffeic acid phenethyl ester inhibits the reaction [Fructose results in increased expression of HMOX1 protein]; caffeic acid phenethyl ester inhibits the reaction [Streptozocin results in increased expression of HMOX1 protein] caffeic acid phenethyl ester analog results in increased expression of HMOX1 mRNA; caffeic acid phenethyl ester analog results in increased expression of HMOX1 protein; caffeic acid phenethyl ester results in increased expression of HMOX1 mRNA; caffeic acid phenethyl ester results in increased expression of HMOX1 protein |
CTD |
PMID:20226179 PMID:20950636 PMID:21472898 PMID:23942037 PMID:24508943 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnrnpr |
heterogeneous nuclear ribonucleoprotein R |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of HNRNPR mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:154,668,194...154,699,967
Ensembl chr 5:154,668,179...154,699,966
|
|
G |
Hpcal4 |
hippocalcin-like 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of HPCAL4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:140,870,127...140,882,242
Ensembl chr 5:140,870,140...140,882,244
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of HSPA2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:99,433,575...99,436,288
Ensembl chr 6:99,433,550...99,436,289
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of HSPA5 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of HSPA5 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of HSPA5 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of HSPB1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hspb2 |
heat shock protein family B (small) member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of HSPB2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:55,176,648...55,178,227
Ensembl chr 8:55,176,847...55,177,818
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3A mRNA; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3A mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908
|
|
G |
Idh3b |
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit beta |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3B mRNA; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3B mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 3:122,808,564...122,813,638
Ensembl chr 3:122,808,564...122,813,583
|
|
G |
Idh3g |
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3G mRNA; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3G mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr X:156,999,803...157,008,735
Ensembl chr X:156,999,826...157,008,733
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of IDO1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr16:72,216,326...72,228,098
Ensembl chr16:72,216,326...72,228,098
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with caffeic acid phenethyl ester] results in decreased expression of IFNG protein; caffeic acid phenethyl ester inhibits the reaction [IFNG protein promotes the reaction [decitabine results in increased expression of PLA2G2A protein]] |
CTD |
PMID:18953428 PMID:24289642 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igbp1 |
immunoglobulin binding protein 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of IGBP1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr X:70,322,764...70,345,005
Ensembl chr X:70,322,755...70,345,005
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [AIMP1 protein results in increased expression of IL12B mRNA] |
CTD |
PMID:16365417 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of IL18 mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of IL1A mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of IL1B mRNA; caffeic acid phenethyl ester inhibits the reaction [GJB1 protein results in decreased expression of IL1B mRNA]; caffeic acid phenethyl ester inhibits the reaction [GJB1 protein results in decreased expression of IL1B protein] |
CTD |
PMID:15350541 PMID:20360939 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of IL2 mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Insrr |
insulin receptor-related receptor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of INSRR mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:187,161,817...187,181,400
Ensembl chr 2:187,162,017...187,181,395
|
|
G |
Ip6k2 |
inositol hexakisphosphate kinase 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of IP6K2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 8:117,574,136...117,599,849
Ensembl chr 8:117,574,161...117,599,848
|
|
G |
Irs1 |
insulin receptor substrate 1 |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of IRS1 mRNA |
CTD |
PMID:21467634 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions increases expression |
ISO |
caffeic acid phenethyl ester promotes the reaction [Tretinoin results in increased expression of ITGAM protein] caffeic acid phenethyl ester results in increased expression of ITGAM protein |
CTD |
PMID:16766008 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR1 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR1 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR1 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 4:140,247,297...140,580,749
Ensembl chr 4:140,247,313...140,580,748
|
|
G |
Itpr2 |
inositol 1,4,5-trisphosphate receptor, type 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR2 mRNA; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 4:180,423,452...180,800,088
Ensembl chr 4:180,538,389...180,722,358
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in increased expression of JUN mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kalrn |
kalirin, RhoGEF kinase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KALRN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:69,484,293...70,025,682
Ensembl chr11:69,484,293...70,025,633
|
|
G |
Kcng3 |
potassium voltage-gated channel modifier subfamily G member 3 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of KCNG3 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 6:6,794,808...6,842,758
Ensembl chr 6:6,794,808...6,842,758
|
|
G |
Kcnh5 |
potassium voltage-gated channel subfamily H member 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KCNH5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:97,872,831...98,157,087
Ensembl chr 6:97,872,831...98,157,087
|
|
G |
Kcnj2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of KCNJ2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:99,429,337...99,442,520
Ensembl chr10:99,437,436...99,439,114
|
|
G |
Kcnmb2 |
potassium calcium-activated channel subfamily M regulatory beta subunit 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KCNMB2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:118,276,298...118,585,321
Ensembl chr 2:118,546,829...118,586,699
|
|
G |
Kcnq2 |
potassium voltage-gated channel subfamily Q member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KCNQ2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:176,585,897...176,645,029
Ensembl chr 3:176,589,906...176,644,951
|
|
G |
Kcnt2 |
potassium sodium-activated channel subfamily T member 2 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of KCNT2 mRNA |
CTD |
PMID:26100633 |
|
NCBI chr13:57,130,855...57,520,263
Ensembl chr13:57,131,395...57,521,836
|
|
G |
Kif6 |
kinesin family member 6 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of KIF6 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 9:13,016,973...13,311,971
Ensembl chr 9:13,030,673...13,311,924
|
|
G |
Klhl17 |
kelch-like family member 17 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of KLHL17 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:173,654,238...173,659,706
Ensembl chr 5:173,654,860...173,659,675
|
|
G |
Lalba |
lactalbumin, alpha |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of LALBA mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:140,088,420...140,096,347
Ensembl chr 7:140,088,421...140,090,922
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of LEP mRNA; caffeic acid phenethyl ester results in decreased expression of LEP protein |
CTD |
PMID:21467634 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Leprot |
leptin receptor overlapping transcript |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of LEPROT mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:120,498,910...120,511,011
Ensembl chr 5:120,498,883...120,511,017
|
|
G |
Lgi1 |
leucine-rich, glioma inactivated 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of LGI1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:256,955,944...256,996,835
Ensembl chr 1:256,955,652...256,999,253
|
|
G |
Lmna |
lamin A/C |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of LMNA mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
|
|
G |
LOC100363405 |
hypothetical LOC100363405 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of ZFP37 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 5:77,265,335...77,294,739
Ensembl chr 5:77,266,842...77,294,765
|
|
G |
Lrrc15 |
leucine rich repeat containing 15 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of LRRC15 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:74,040,846...74,052,179
Ensembl chr11:74,050,166...74,051,902
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
affects phosphorylation |
ISO |
caffeic acid phenethyl ester analog affects the phosphorylation of MAPK1 protein |
CTD |
PMID:32125059 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MAPK14 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
affects phosphorylation |
ISO |
caffeic acid phenethyl ester analog affects the phosphorylation of MAPK3 protein |
CTD |
PMID:32125059 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Me1 |
malic enzyme 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ME1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:94,256,830...94,368,834
Ensembl chr 8:94,256,839...94,368,834
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of MFN2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of MFN2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 5:164,684,244...164,715,414
Ensembl chr 5:164,684,509...164,714,145
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity multiple interactions |
EXP |
caffeic acid phenethyl ester results in decreased activity of MMP2 protein NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in decreased activity of MMP2 protein] |
CTD |
PMID:20836997 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of MMP3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression decreases activity multiple interactions |
ISO EXP |
caffeic acid phenethyl ester results in decreased expression of MMP9 protein caffeic acid phenethyl ester results in decreased activity of MMP9 protein NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in decreased activity of MMP9 protein] |
CTD |
PMID:20433813 PMID:20836997 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Doxorubicin results in increased activity of MPO protein]; caffeic acid phenethyl ester inhibits the reaction [Isoproterenol results in increased activity of MPO protein]; caffeic acid phenethyl ester inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein] |
CTD |
PMID:15369732 PMID:20693123 PMID:21472898 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mprip |
myosin phosphatase Rho interacting protein |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MPRIP mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:46,018,397...46,133,580
Ensembl chr10:46,018,659...46,133,571
|
|
G |
Msx2 |
msh homeobox 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MSX2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr17:11,683,862...11,689,527
Ensembl chr17:11,683,862...11,689,527
|
|
G |
Mterf1 |
mitochondrial transcription termination factor 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MTERF1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:27,365,310...27,372,374
Ensembl chr 4:27,365,376...27,372,372
|
|
G |
Mtus1 |
microtubule associated scaffold protein 1 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of MTUS1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr16:54,240,892...54,386,131
Ensembl chr16:54,291,251...54,386,129
|
|
G |
Muc1 |
mucin 1, cell surface associated |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MUC1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:188,543,137...188,547,874
Ensembl chr 2:188,543,137...188,547,874
|
|
G |
Mug1 |
murinoglobulin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PZP mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:154,676,382...154,729,288
Ensembl chr 4:154,391,647...154,729,310
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of MXI1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:274,030,748...274,090,071
Ensembl chr 1:274,030,978...274,090,071
|
|
G |
Myo9a |
myosin IXA |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of MYO9A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:64,573,248...64,777,607
Ensembl chr 8:64,573,358...64,777,543
|
|
G |
Nat8b |
N-acetyltransferase 8B |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NAT8B mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:117,606,022...117,607,366
Ensembl chr 4:117,606,022...117,607,428 Ensembl chr 4:117,606,022...117,607,428
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NCAM1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:53,836,797...54,134,881
Ensembl chr 8:53,839,098...53,901,358
|
|
G |
Ndufa10l1 |
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10-like 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NDUFA10L1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:62,796,951...62,798,384
Ensembl chr 6:62,796,456...62,798,384
|
|
G |
Neo1 |
neogenin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NEO1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:63,649,871...63,756,394
Ensembl chr 8:63,653,266...63,750,531
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester promotes the reaction [Nitrogen Mustard Compounds results in increased expression of NFE2L2 protein] caffeic acid phenethyl ester inhibits the reaction [Bleomycin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:17204746 PMID:23570914 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfia |
nuclear factor I/A |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NFIA mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:116,421,895...116,750,381
Ensembl chr 5:116,420,690...116,751,416
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Zymosan results in increased activity of [NFKB1 protein binds to RELA protein]] caffeic acid phenethyl ester results in decreased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:11259437 PMID:16052512 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in increased expression of NFKB2 protein] |
CTD |
PMID:20420878 |
|
NCBI chr 1:266,050,634...266,059,277
Ensembl chr 1:266,053,002...266,059,256
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases phosphorylation |
EXP |
caffeic acid phenethyl ester results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:20836997 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nfya |
nuclear transcription factor Y subunit alpha |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of NFYA mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 9:14,551,752...14,577,002
Ensembl chr 9:14,551,758...14,576,967
|
|
G |
Ngf |
nerve growth factor |
increases expression |
EXP |
caffeic acid phenethyl ester results in increased expression of NGF protein |
CTD |
PMID:20836997 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression affects response to substance multiple interactions |
EXP |
caffeic acid phenethyl ester results in increased expression of NGFR protein NGFR protein affects the susceptibility to caffeic acid phenethyl ester NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in decreased activity of MMP2 protein]; NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in decreased activity of MMP9 protein]; NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of GFAP protein]; NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of RHOB protein]; NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of S100B protein] |
CTD |
PMID:20836997 |
|
NCBI chr10:83,389,828...83,408,061
Ensembl chr10:83,389,847...83,408,061
|
|
G |
Nog |
noggin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NOG mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:76,811,759...76,813,386
Ensembl chr10:76,811,759...76,813,386
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of NOS2 protein |
CTD |
PMID:15469948 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Notch2 |
notch receptor 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NOTCH2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:200,187,184...200,320,403
Ensembl chr 2:200,187,179...200,320,215
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Particulate Matter results in increased expression of NOX4 mRNA]; caffeic acid phenethyl ester inhibits the reaction [Particulate Matter results in increased expression of NOX4 protein]; caffeic acid phenethyl ester inhibits the reaction [Vehicle Emissions results in increased expression of NOX4 mRNA]; caffeic acid phenethyl ester inhibits the reaction [Vehicle Emissions results in increased expression of NOX4 protein] |
CTD |
PMID:24224404 |
|
NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of NR0B2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of NR0B2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
[[NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester] which results in decreased expression of INS1 protein; [[NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester] which results in increased abundance of Citric Acid; [[NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester] which results in increased abundance of Fumarates; [[NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester] which results in increased abundance of Ketoglutaric Acids; [[NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester] which results in increased abundance of malic acid; [NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of CERS4 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DDIT3 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of DEGS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of HSPA5 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR1 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of ITPR2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of PACS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD3 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD4 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SPTLC2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of VDAC1 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased activity of CS protein]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of CS mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3A mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3B mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in increased expression of IDH3G mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Nrtn |
neurturin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of NRTN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 9:10,299,881...10,306,599
Ensembl chr 9:10,305,470...10,306,597
|
|
G |
Nup88 |
nucleoporin 88 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of NUP88 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:57,581,828...57,606,171
Ensembl chr10:57,581,828...57,606,171
|
|
G |
Odf1 |
outer dense fiber of sperm tails 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ODF1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:77,066,580...77,074,712
Ensembl chr 7:77,066,955...77,074,711
|
|
G |
Olig1 |
oligodendrocyte transcription factor 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of OLIG1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:31,428,377...31,430,519
Ensembl chr11:31,428,358...31,430,517
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in increased expression of OLR1 protein] |
CTD |
PMID:24145059 |
|
NCBI chr 4:163,239,853...163,261,937
Ensembl chr 4:163,239,849...163,261,958
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of OPA1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:74,717,600...74,793,902
Ensembl chr11:74,720,254...74,793,803
|
|
G |
Pacs2 |
phosphofurin acidic cluster sorting protein 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of PACS2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of PACS2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of PACS2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 6:137,824,136...137,889,144
Ensembl chr 6:137,824,213...137,887,418
|
|
G |
Pard3 |
par-3 family cell polarity regulator |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PARD3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr19:60,017,746...60,580,628
Ensembl chr19:60,017,746...60,580,651
|
|
G |
Pc |
pyruvate carboxylase |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased activity of PC protein; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased activity of PC protein] |
CTD |
PMID:28223344 |
|
NCBI chr 1:219,759,157...219,859,854
Ensembl chr 1:219,759,183...219,859,848
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PCK1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pcsk1n |
proprotein convertase subtilisin/kexin type 1 inhibitor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PCSK1N mRNA |
CTD |
PMID:20360939 |
|
NCBI chr X:15,324,263...15,327,705
Ensembl chr X:15,425,078...15,428,518 Ensembl chr X:15,425,078...15,428,518
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of PCSK2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 3:137,618,891...137,923,385
Ensembl chr 3:137,618,898...137,925,605
|
|
G |
Pcsk6 |
proprotein convertase subtilisin/kexin type 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of PCSK6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:126,749,508...126,947,392
Ensembl chr 1:126,749,508...126,947,392
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of PDGFRB mRNA |
CTD |
PMID:20360939 |
|
NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
|
|
G |
Per3 |
period circadian regulator 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PER3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:168,088,126...168,123,482
Ensembl chr 5:168,086,998...168,123,395
|
|
G |
Pfkp |
phosphofructokinase, platelet |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PFKP mRNA |
CTD |
PMID:20360939 |
|
NCBI chr17:68,510,765...68,574,387
Ensembl chr17:68,511,064...68,559,471
|
|
G |
Phkg2 |
phosphorylase kinase catalytic subunit gamma 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of PHKG2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:199,019,298...199,032,053
Ensembl chr 1:199,019,289...199,032,052
|
|
G |
Pias2 |
protein inhibitor of activated STAT, 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PIAS2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr18:73,479,863...73,524,956
Ensembl chr18:73,378,662...73,524,956
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [IFNG protein promotes the reaction [decitabine results in increased expression of PLA2G2A protein]] |
CTD |
PMID:18953428 |
|
NCBI chr 5:157,282,650...157,285,295
Ensembl chr 5:157,282,669...157,285,328
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PLCG1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:156,727,642...156,758,307
Ensembl chr 3:156,727,642...156,758,307
|
|
G |
Plekha5 |
pleckstrin homology domain containing A5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PLEKHA5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:174,605,462...174,774,692
Ensembl chr 4:174,605,476...174,774,693
|
|
G |
Pold1 |
DNA polymerase delta 1, catalytic subunit |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of POLD1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:100,538,066...100,554,105
Ensembl chr 1:100,537,900...100,554,488
|
|
G |
Polg |
DNA polymerase gamma, catalytic subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of POLG mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:141,172,117...141,188,893
Ensembl chr 1:141,172,531...141,188,031
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of PPARG mRNA |
CTD |
PMID:21467634 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PPP2R2A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr15:43,673,958...43,733,182
Ensembl chr15:43,673,960...43,733,182
|
|
G |
Ppp4c |
protein phosphatase 4, catalytic subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PPP4C mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:198,219,012...198,225,775
Ensembl chr 1:198,219,054...198,225,580
|
|
G |
Prep |
prolyl endopeptidase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PREP mRNA |
CTD |
PMID:20360939 |
|
NCBI chr20:50,172,618...50,269,992
Ensembl chr20:50,172,618...50,269,992
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PRKACA mRNA |
CTD |
PMID:20360939 |
|
NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PRKAR2A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:117,486,085...117,548,768
Ensembl chr 8:117,486,083...117,546,370
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PRKCE mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
|
|
G |
Prok2 |
prokineticin 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of PROK2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 4:132,157,556...132,171,244
Ensembl chr 4:132,157,556...132,171,153
|
|
G |
Prom1 |
prominin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of PROM1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:71,532,321...71,637,400
Ensembl chr14:71,533,063...71,637,417
|
|
G |
Prss12 |
serine protease 12 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PRSS12 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:227,657,983...227,717,884
Ensembl chr 2:227,657,983...227,717,884
|
|
G |
Prss3 |
serine protease 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PRSS3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:70,614,524...70,617,998
Ensembl chr 4:70,614,524...70,617,998
|
|
G |
Psma7 |
proteasome 20S subunit alpha 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of PSMA7 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:175,420,042...175,426,384
Ensembl chr 3:175,420,039...175,426,395
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
decreases phosphorylation |
ISO |
caffeic acid phenethyl ester results in decreased phosphorylation of PTK2 protein |
CTD |
PMID:10741720 |
|
NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of PTPN1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:164,665,462...164,711,936
Ensembl chr 3:164,665,532...164,711,848
|
|
G |
Ramp1 |
receptor activity modifying protein 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RAMP1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 9:98,313,632...98,364,206
Ensembl chr 9:98,313,632...98,364,205
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases activity multiple interactions increases expression |
ISO |
caffeic acid phenethyl ester results in increased activity of RARA protein [Tretinoin co-treated with caffeic acid phenethyl ester] results in increased expression of RARA mRNA; [Tretinoin co-treated with caffeic acid phenethyl ester] results in increased expression of RARA protein; caffeic acid phenethyl ester promotes the reaction [Tretinoin results in increased activity of RARA protein] caffeic acid phenethyl ester results in increased expression of RARA mRNA; caffeic acid phenethyl ester results in increased expression of RARA protein |
CTD |
PMID:16766008 |
|
NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression |
EXP |
caffeic acid phenethyl ester results in decreased expression of RB1 protein modified form |
CTD |
PMID:15885897 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rcan1 |
regulator of calcineurin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of RCAN1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:32,539,689...32,620,274
Ensembl chr11:32,539,683...32,550,539
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Paclitaxel results in increased activity of RELA protein]; caffeic acid phenethyl ester inhibits the reaction [TNF protein results in increased activity of RELA protein]; caffeic acid phenethyl ester results in decreased activity of [NFKB1 protein binds to RELA protein] caffeic acid phenethyl ester inhibits the reaction [Zymosan results in increased activity of [NFKB1 protein binds to RELA protein]] |
CTD |
PMID:11259437 PMID:15291876 PMID:16052512 PMID:26562779 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rem2 |
RRAD and GEM like GTPase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of REM2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr15:33,121,273...33,125,752
Ensembl chr15:33,121,273...33,125,752
|
|
G |
Ret |
ret proto-oncogene |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RET mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372
|
|
G |
Retn |
resistin |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of RETN protein |
CTD |
PMID:21467634 |
|
NCBI chr12:2,201,909...2,203,649
Ensembl chr12:2,201,891...2,204,249
|
|
G |
Rfc1 |
replication factor C subunit 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RFC1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:44,627,528...44,702,205
Ensembl chr14:44,580,216...44,702,203
|
|
G |
Rgs6 |
regulator of G-protein signaling 6 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RGS6 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:106,310,442...106,598,668
Ensembl chr 6:106,496,992...106,602,139
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions increases expression |
EXP |
NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of RHOB protein] |
CTD |
PMID:20836997 |
|
NCBI chr 6:33,689,127...33,691,301
Ensembl chr 6:33,689,127...33,691,301
|
|
G |
Rpe65 |
retinoid isomerohydrolase RPE65 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RPE65 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:266,141,581...266,169,197
Ensembl chr 2:266,141,581...266,169,197
|
|
G |
Rph3a |
rabphilin 3A |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RPH3A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr12:41,073,296...41,149,799
Ensembl chr12:41,073,824...41,148,490
|
|
G |
Rpl26 |
ribosomal protein L26 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of RPL26 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr10:55,492,417...55,495,547
Ensembl chr10:55,492,404...55,496,012
|
|
G |
Rps3a |
ribosomal protein S3a |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RPS3A mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 2:185,440,477...185,444,846
Ensembl chr 2:185,440,291...185,444,897
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Mustard Compounds results in increased phosphorylation of RPS6KA2 protein]; caffeic acid phenethyl ester inhibits the reaction [Nitrogen Mustard Compounds results in increased phosphorylation of RPS6KA2 protein] |
CTD |
PMID:17204746 |
|
NCBI chr 1:53,219,346...53,499,445
Ensembl chr 1:53,360,157...53,499,445
|
|
G |
Rps9 |
ribosomal protein S9 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RPS9 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:64,086,625...64,090,023
Ensembl chr 1:64,018,125...64,090,021
|
|
G |
RT1-A3 |
RT1 class I, locus A3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RT1-A3 mRNA |
CTD |
PMID:20360939 |
|
|
|
G |
RT1-N1 |
RT1 class Ib, locus N1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RT1-N1 mRNA |
CTD |
PMID:20360939 |
|
|
|
G |
RT1-S3 |
RT1 class Ib, locus S3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of RT1-S3 mRNA; [Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of RT1-S3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr20:3,176,124...3,180,825
Ensembl chr20:3,176,107...3,179,818
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein] |
CTD |
PMID:28363435 |
|
NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
|
|
G |
S100b |
S100 calcium binding protein B |
increases expression multiple interactions |
EXP |
caffeic acid phenethyl ester results in increased expression of S100B protein NGFR protein affects the susceptibility to [caffeic acid phenethyl ester results in increased expression of S100B protein] |
CTD |
PMID:20836997 |
|
NCBI chr20:13,130,633...13,142,856
Ensembl chr20:13,130,636...13,142,856
|
|
G |
Scaper |
S-phase cyclin A-associated protein in the ER |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SCAPER mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:60,127,039...60,593,568
Ensembl chr 8:60,126,624...60,570,058
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of SCD1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of SCNN1G mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:191,704,397...191,738,271
Ensembl chr 1:191,704,311...191,738,268
|
|
G |
Sdc4 |
syndecan 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of SDC4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:160,872,503...160,891,190
Ensembl chr 3:160,872,503...160,891,190
|
|
G |
Sds |
serine dehydratase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SDS mRNA |
CTD |
PMID:20360939 |
|
NCBI chr12:41,620,429...41,627,741
Ensembl chr12:41,620,393...41,627,741
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SERPINB2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr13:27,449,907...27,463,015
Ensembl chr13:27,449,934...27,463,010
|
|
G |
Serpinb5 |
serpin family B member 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SERPINB5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr13:26,903,052...26,923,250
Ensembl chr13:26,903,052...26,923,250
|
|
G |
Serpinf1 |
serpin family F member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SERPINF1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:62,241,750...62,254,145
Ensembl chr10:62,241,756...62,254,287
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SIRT2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:86,948,866...86,971,954
Ensembl chr 1:86,948,918...86,971,952
|
|
G |
Slc12a8 |
solute carrier family 12, member 8 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC12A8 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr11:70,344,771...70,499,202
Ensembl chr11:70,344,797...70,499,200
|
|
G |
Slc14a2 |
solute carrier family 14 member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC14A2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr18:74,508,070...74,941,389
Ensembl chr18:74,546,220...74,688,551 Ensembl chr18:74,546,220...74,688,551
|
|
G |
Slc17a8 |
solute carrier family 17 member 8 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC17A8 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 7:30,215,231...30,274,993
Ensembl chr 7:30,216,104...30,274,984
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC1A1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:246,955,017...247,035,159
Ensembl chr 1:246,954,980...247,037,056
|
|
G |
Slc1a5 |
solute carrier family 1 member 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC1A5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:78,710,686...78,724,789
Ensembl chr 1:78,710,539...78,724,794
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC38A2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:138,088,654...138,100,869
Ensembl chr 7:138,088,649...138,100,841
|
|
G |
Slc45a1 |
solute carrier family 45, member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC45A1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:167,672,134...167,696,331
Ensembl chr 5:167,672,145...167,696,348
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC4A2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 4:7,264,677...7,282,355
Ensembl chr 4:7,264,683...7,281,223
|
|
G |
Slc51a |
solute carrier family 51 subunit alpha |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SLC51A mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SLC51A mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr11:71,533,078...71,547,476
Ensembl chr11:71,533,078...71,547,476
|
|
G |
Slc51b |
solute carrier family 51 subunit beta |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SLC51B mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SLC51B mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SLC6A9 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:136,669,674...136,703,702
Ensembl chr 5:136,669,674...136,703,697
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD3 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD3 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD3 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr19:38,237,963...38,321,572
Ensembl chr19:38,237,965...38,321,528
|
|
G |
Smpd4 |
sphingomyelin phosphodiesterase 4 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD4 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD4 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SMPD4 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr11:87,522,971...87,546,687
Ensembl chr11:87,522,971...87,546,687
|
|
G |
Snd1 |
staphylococcal nuclease and tudor domain containing 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of SND1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:55,772,377...56,171,669
Ensembl chr 4:55,772,377...56,171,668
|
|
G |
Soat1 |
sterol O-acyltransferase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SOAT1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr13:74,035,258...74,077,759
Ensembl chr13:74,035,080...74,077,783
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in decreased expression of SOD1 protein] |
CTD |
PMID:22692362 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sox10 |
SRY-box transcription factor 10 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SOX10 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:120,393,238...120,403,523
Ensembl chr 7:120,393,254...120,403,523
|
|
G |
Spa17 |
sperm autoantigenic protein 17 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SPA17 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:40,066,954...40,078,131
Ensembl chr 8:40,067,076...40,078,165
|
|
G |
Sphk1 |
sphingosine kinase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of SPHK1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:105,498,728...105,504,401
Ensembl chr10:105,498,728...105,504,393
|
|
G |
Sptlc2 |
serine palmitoyltransferase, long chain base subunit 2 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SPTLC2 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SPTLC2 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of SPTLC2 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr 6:111,334,408...111,417,960
Ensembl chr 6:111,339,136...111,417,954
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [Cyclosporine results in increased phosphorylation of STAT3 protein] caffeic acid phenethyl ester analog affects the expression of and affects the phosphorylation of STAT3 protein |
CTD |
PMID:22155090 PMID:32125059 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Strn |
striatin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of STRN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 6:1,232,729...1,319,603
Ensembl chr 6:1,237,758...1,319,541
|
|
G |
Stx2 |
syntaxin 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of STX2 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr12:31,324,203...31,360,249
Ensembl chr12:31,335,372...31,360,254
|
|
G |
Tec |
tec protein tyrosine kinase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of TEC mRNA |
CTD |
PMID:20360939 |
|
NCBI chr14:37,918,884...38,027,953
Ensembl chr14:37,918,652...38,027,925
|
|
G |
Tg |
thyroglobulin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of TG mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:107,467,260...107,652,897
Ensembl chr 7:107,467,260...107,652,899
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of TGFB2 mRNA] |
CTD |
PMID:16085347 |
|
NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
|
|
G |
Tgm4 |
transglutaminase 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of TGM4 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 8:132,117,279...132,157,485
Ensembl chr 8:132,120,452...132,157,485
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of TH mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Tk1 |
thymidine kinase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of TK1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:106,817,556...106,828,888
Ensembl chr10:106,817,601...106,828,884
|
|
G |
Tkt |
transketolase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of TKT mRNA |
CTD |
PMID:20360939 |
|
NCBI chr16:6,609,670...6,634,608
Ensembl chr16:6,609,668...6,634,595
|
|
G |
Tmod2 |
tropomodulin 2 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of TMOD2 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 8:82,505,947...82,547,450
Ensembl chr 8:82,506,934...82,533,689
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Particulate Matter results in increased expression of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [TNF protein results in increased activity of RELA protein]; caffeic acid phenethyl ester inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; caffeic acid phenethyl ester inhibits the reaction [Vehicle Emissions results in increased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Vehicle Emissions results in increased expression of TNF protein] caffeic acid phenethyl ester inhibits the reaction [Fructose results in increased expression of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [Streptozocin results in increased expression of TNF protein] caffeic acid phenethyl ester results in decreased expression of TNF protein caffeic acid phenethyl ester inhibits the reaction [Okadaic Acid results in increased expression of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [Zymosan results in increased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Zymosan results in increased expression of TNF protein] |
CTD |
PMID:10757128 PMID:11259437 PMID:15291876 PMID:16085347 PMID:16271621 PMID:21467634 PMID:21472898 PMID:24224404 PMID:24508943 PMID:26562779 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with caffeic acid phenethyl ester] results in increased expression of TNFRSF10A mRNA |
CTD |
PMID:24289642 |
|
NCBI chr15:51,433,853...51,464,215
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA] |
CTD |
PMID:28363435 |
|
NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:28363435 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
G |
Tnnt1 |
troponin T1, slow skeletal type |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in increased expression of TNNT1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 1:72,889,270...72,899,629
Ensembl chr 1:72,889,270...72,899,659
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO EXP |
caffeic acid phenethyl ester inhibits the reaction [Folic Acid results in increased expression of TP53 protein]; caffeic acid phenethyl ester inhibits the reaction [Mustard Compounds results in increased phosphorylation of TP53 protein]; caffeic acid phenethyl ester inhibits the reaction [Nitrogen Mustard Compounds results in increased phosphorylation of TP53 protein]; caffeic acid phenethyl ester inhibits the reaction [sodium arsenite results in decreased expression of TP53 protein] caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of TP53 mRNA] |
CTD |
PMID:17204746 PMID:20360939 PMID:22692362 PMID:26056802 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Trim17 |
tripartite motif-containing 17 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in increased expression of TRIM17 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:45,307,007...45,314,823
Ensembl chr10:45,297,937...45,314,837
|
|
G |
Ttn |
titin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of TTN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 3:63,565,160...63,837,815
|
|
G |
Txnl1 |
thioredoxin-like 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of TXNL1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr18:59,056,454...59,086,278
Ensembl chr18:59,059,375...59,086,256
|
|
G |
Tyr |
tyrosinase |
multiple interactions increases oxidation affects response to substance |
ISO |
[TYR protein affects the susceptibility to caffeic acid phenethyl ester] which affects the abundance of Glutathione; [TYR protein affects the susceptibility to caffeic acid phenethyl ester] which affects the abundance of Reactive Oxygen Species; ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of Ascorbic Acid]; ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; ethylenediamine inhibits the reaction [TYR protein results in increased oxidation of caffeic acid phenethyl ester]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of Ascorbic Acid]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [TYR protein results in increased oxidation of caffeic acid phenethyl ester]; TYR protein results in increased metabolism of and results in increased susceptibility to caffeic acid phenethyl ester [TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of Ascorbic Acid; [TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD; TYR protein results in increased oxidation of caffeic acid phenethyl ester |
CTD |
PMID:20685355 PMID:21458432 |
|
NCBI chr 1:151,012,598...151,106,802
Ensembl chr 1:151,012,598...151,106,802
|
|
G |
Vamp8 |
vesicle-associated membrane protein 8 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of VAMP8 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:100,250,301...100,252,756
Ensembl chr 4:100,250,301...100,252,755
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
caffeic acid phenethyl ester inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:16271621 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
G |
Vcpip1 |
valosin containing protein interacting protein 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of VCPIP1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 5:9,231,180...9,257,821
Ensembl chr 5:9,230,984...9,257,934
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of VDAC1 mRNA; GW 4064 inhibits the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of VDAC1 mRNA]; NR1H4 protein affects the reaction [[caffeic acid phenethyl ester co-treated with Dietary Fats] results in decreased expression of VDAC1 mRNA] |
CTD |
PMID:28223344 |
|
NCBI chr10:37,724,915...37,752,827
Ensembl chr10:37,724,915...37,752,826
|
|
G |
Vtn |
vitronectin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of VTN mRNA |
CTD |
PMID:20360939 |
|
NCBI chr10:65,767,960...65,771,040
Ensembl chr10:65,767,053...65,771,038
|
|
G |
Vwf |
von Willebrand factor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of VWF mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:158,085,059...158,219,525
Ensembl chr 4:158,088,505...158,219,523
|
|
G |
Wrnip1 |
WRN helicase interacting protein 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of WRNIP1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr17:32,933,395...32,953,641
Ensembl chr17:32,933,396...32,953,641
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
caffeic acid phenethyl ester results in decreased expression of XIAP protein |
CTD |
PMID:15291876 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of XRCC5 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 9:79,659,275...79,748,050
Ensembl chr 9:79,659,251...79,748,078
|
|
G |
Ybx3 |
Y box binding protein 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of YBX3 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:165,606,819...165,630,041
Ensembl chr 4:165,606,819...165,630,118
|
|
G |
Yy1 |
YY1 transcription factor |
multiple interactions |
EXP |
caffeic acid phenethyl ester inhibits the reaction [Diethylnitrosamine results in decreased expression of YY1 mRNA] |
CTD |
PMID:20360939 |
|
NCBI chr 6:132,702,443...132,726,848
Ensembl chr 6:132,702,448...132,727,046
|
|
G |
Zfp180 |
zinc finger protein 180 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ZFP180 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 1:80,920,745...80,940,038
Ensembl chr 1:80,920,747...80,940,040
|
|
G |
Zfp384 |
zinc finger protein 384 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ZFP384 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 4:157,523,083...157,552,606
Ensembl chr 4:157,523,110...157,552,596
|
|
G |
Zfp394 |
zinc finger protein 394 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ZNF394 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr12:11,179,323...11,187,362
Ensembl chr12:11,179,329...11,187,380
|
|
G |
Zhx1 |
zinc fingers and homeoboxes 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of ZHX1 mRNA |
CTD |
PMID:20360939 |
|
NCBI chr 7:97,915,280...97,944,787
Ensembl chr 7:97,915,581...97,944,491
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
EXP |
rosmarinic acid results in decreased expression of ACTA2 protein rosmarinic acid inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:28789951 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions decreases expression |
ISO |
[rosmarinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which affects the localization of PROCR protein; [rosmarinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which results in decreased cleavage of and results in decreased secretion of PROCR protein; [rosmarinic acid results in decreased expression of ADAM17 protein] inhibits the reaction [IL1B protein affects the localization of PROCR protein]; [rosmarinic acid results in decreased expression of ADAM17 protein] inhibits the reaction [IL1B protein results in increased cleavage of and results in increased secretion of PROCR protein]; [rosmarinic acid results in decreased expression of ADAM17 protein] inhibits the reaction [TNF protein affects the localization of PROCR protein]; [rosmarinic acid results in decreased expression of ADAM17 protein] inhibits the reaction [TNF protein results in increased cleavage of and results in increased secretion of PROCR protein]; rosmarinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein] |
CTD |
PMID:23774263 |
|
NCBI chr 6:43,400,525...43,448,280
Ensembl chr 6:43,400,528...43,448,280
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
rosmarinic acid inhibits the reaction [Cadmium affects the localization of AIFM1 protein] |
CTD |
PMID:23548128 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
rosmarinic acid inhibits the reaction [Cadmium results in increased activity of CASP3 protein] rosmarinic acid inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein] |
CTD |
PMID:23548128 PMID:28815802 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions increases activity increases expression |
ISO |
rosmarinic acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased activity of CAT protein]; rosmarinic acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of CAT mRNA] rosmarinic acid results in increased activity of CAT protein rosmarinic acid results in increased expression of CAT mRNA |
CTD |
PMID:31610155 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions decreases expression |
EXP |
rosmarinic acid inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein] rosmarinic acid results in decreased expression of CCN2 mRNA |
CTD |
PMID:28789951 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP |
rosmarinic acid inhibits the reaction [TGFB1 protein results in increased expression of CCND1 protein] |
CTD |
PMID:28789951 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cd68 |
Cd68 molecule |
decreases expression |
EXP |
rosmarinic acid results in decreased expression of CD68 protein |
CTD |
PMID:28789951 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression multiple interactions |
ISO EXP |
rosmarinic acid results in decreased expression of COL1A1 mRNA rosmarinic acid inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27235791 PMID:28789951 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions decreases expression |
EXP |
rosmarinic acid inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] rosmarinic acid results in decreased expression of COL3A1 mRNA |
CTD |
PMID:28789951 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Crp |
C-reactive protein |
affects expression multiple interactions |
EXP |
rosmarinic acid affects the expression of CRP protein 2-chloro-5-nitrobenzanilide inhibits the reaction [rosmarinic acid affects the expression of CRP protein]; T 0070907 inhibits the reaction [rosmarinic acid affects the expression of CRP protein] |
CTD |
PMID:28744220 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions decreases expression |
ISO |
rosmarinic acid inhibits the reaction [Particulate Matter results in increased expression of CXCL1 protein]; rosmarinic acid inhibits the reaction [Vehicle Emissions results in increased expression of CXCL1 protein] rosmarinic acid results in decreased expression of CXCL1 mRNA |
CTD |
PMID:12684091 PMID:26804033 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Des |
desmin |
multiple interactions |
EXP |
rosmarinic acid inhibits the reaction [TGFB1 protein results in increased expression of DES protein] |
CTD |
PMID:28789951 |
|
NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression |
ISO |
rosmarinic acid results in decreased expression of DNMT1 protein |
CTD |
PMID:21078381 |
|
NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
rosmarinic acid results in decreased expression of FN1 mRNA |
CTD |
PMID:26804033 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
rosmarinic acid results in decreased expression of FOS protein |
CTD |
PMID:28789951 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
decreases activity |
EXP |
rosmarinic acid results in decreased activity of GPT protein |
CTD |
PMID:25455894 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions increases expression |
ISO |
rosmarinic acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of GPX1 mR | |